 
Effects of Transcranial Alternating Current Stimulation (tACS)  
on Memory Recall and Sleep -EEG in Healthy Elderly Participants  
 
 
 
NCT number  [STUDY_ID_REMOVED]  
Document Date  08/15/2023  
 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   1 
Template  Version   2.0            2021- 09-09  
Master Protocol  Document  
 
Title  Effects of Transcranial Alternating Current Stimulation (tACS)  
on Memory Recall and Sleep- EEG in Healthy Elderly Participants   
Sub-Title  
 A Double -Blind, Controlled Cross -Over Pilot Study  
Principal  Investigator  
 Flavio Frohlich, PhD, Carolina Center for Neurostimulation, Department of 
Psychiatry, UNC School of Medicine, Chapel Hill, NC  
(also serving in the role of statistical expert)  
Co-Investigators  
 Andrea Seiler, MD, Carolina Center for Neurostimulation, Department of 
Psychiatry, UNC School of Medicine, Chapel Hill, NC  
 
  
Research  Sites  University of North Carolina at Chapel Hill  
Version  Number   1.4 08/15/2023     
 
   I have read , understood,  and approve d this version of the protocol.     
 Principal Investigator:  
          Date:   ______________  
 
 
  
Statement of C onfidentiality and Nondisclosure     This document is a confidential communication.  Acceptance of this document 
constitutes agreement by the recipient that no unpublished information contained herein will be published or disclosed withou t 
prior written approval of the Principal Investigator or other  participating study leadership, except that this document may be 
disclosed in any medium to appropriate investigators, Institutional Review Board s, Scientific Review Committees , and others who 
are directly involved in the study specified herein under the condition that they keep the information  confidential.  
  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   2 
Template  Version   2.0            2021- 09-09 Table  of Version Changes  
 
Previous  
Version No.  Affected  
Sections  Summary of the Changes  
to the Protocol  Reason for Changes  
1.0 1. SYNOPSIS  
2. AIMS  
3. STUDY 
DESIGN  
4. ELIGIBILITY 
CRITERIA  
5. TREATMENT 
DESIGN  
6. SCHEDULE 
(STUDY VISITS) 
 1. CHANGED AIMS (ADDED ASSOCIATIVE MEMORY , 
ADAPTED EVERYTHING ACCORDING TO 
CLINICALTRIALS .GOV), CHANGED OUTCOMES AND 
STATISTICAL PLAN ACCORDINGLY ; CHANGED EXCLUSION 
(NO AD8  DUE TO ALREADY HIGH COUNT OF 
QUESTIONNAIRES ) 
2. CHANGED AIMS ACCORDING TO 
CLINICALTRIALS .GOV. MADE SLEEP MORE CONCRETE 
(ONLY SPINDLES AND SLOW WAVES ARE OUTCOMES ); 
OTHER NEUROPSYCHOLOGICAL OUTCOMES THAN 
MEMORY SECONDARY OUTCOMES (DÖRTHE THINKS IT 
IS OKAY ) 
3. ADDED TELEPHONE CONTACTS EXPLICITLY ; CHANGED 
ELECTRODES TO F7/P7  AND F8/P8   
4. NO AD8   
5. ADDED WORD ASSOCIATION TEST  
6. ADDED ASSOCIATIVE MEMORY , CHANGED QUESTION 
ABOUT ALCOHOL AND PSYCHOTROPIC 
SUBSTANCES /DRUGS FOR FOLLOW -UP VISITS (NOT LAST 
3M, BUT LAST 24H), RVDLT  ONLY DURING VISIT 2, 
AND RECALL IMMEDIATELY AFTER ENCODING (TO WIN 
TIME FOR ANALYSIS  OF Y-FREQUENCY )   
1.1 1. 
MEASUREMENT 
DESIGN , 
ENROLLMENT , 
STUDY DESIGN  
2. 
EVERYWHERE  
3. SECTION 7 1. RVDLT  FOR Y -FREQUENCY ON VISIT 1 INSTEAD OF 
VISIT 2 (TO HAVE MORE TIME FOR ANALYSIS ) 
2. CHANGED PHONEMATIC /VERBAL  FLUENCY TO 
LETTER FLUENCY (TO HAVE THE SAME VOCABULARY  
3. CHANGED TIMEPOINT OF VISIT 5 FROM DAY 5-9 
AFTER STIMULATION TO DAY 6-9 AFTER STIMULATION 
(VISIT 4 AND 5 NOT ON THE SAME DAY , AND VISIT 4 
ALREADY ON DAY 5 AFTER STIMULATION )  
1.2  1. 4 HOURS OF SLEEP EEG  IS NOT AN EXCLUSION 
CRITERIA (WE WANT TO FIND OUT HOW MANY MANAGE 
TO DO IT )  
2. NOT SHAM, BUT CONTROL FREQUENCY (21 HZ – 10 
HZ WORSENS AUDITORY ATTENTION , 20 HZ IS 
HARMONIC ; ALSO : CLOSER TO 40 HZ, THEREFORE 
SIMILAR SIDE EFFECTS , BUT NOT YET GAMMA ). TEXT 
FROM MODIFICATION : WE ARE NOW TIGHTENING THE 
SCIENTIFIC  CONTRAST SUCH THAT WE CAN DRAW 
CONCLUSIONS ABOUT THE EFFECT OF A SPECIFIC 
STIMULATION FREQUENCY ,  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   3 
Template  Version   2.0            2021- 09-09 WHEREAS OUR PREVIOUS DESIGN ONLY ALLOWED TO 
DRAW CONCLUSIONS ABOUT THE EFFECT OF 
STIMULATION IN  
GENERAL . THUS, WE NOW USE A CONTROL FREQUENCY 
OF 21H Z INSTEAD OF THE ACTIVE SHAM STIMULATION . 
3. TACS  AMPLITUDE IS INDIVIDUALIZED (SAME 
AMPLITUDE FOR BOTH CONDITIONS ; HAS TO BE 
SUPPORTED FOR 1H, THRESHOLDING FOR 21 AND 40 
HZ, LOWER AMPLITUDE IS TAKEN )  
4. NO INDIVIDUALIZED GAMMA , BECAUSE NO 
CLEAR/SINGLE PEAK DURING RVDLT  ACCORDING TO 
JIMIN’S ANALYSIS  
5. ELECTRODE POSITIONING FOR LEAST SIDE EFFECTS : 
T7/8,  P7/8  
6. ACTIGRAPHY ADDED TO SEE IF STIMULATION 
CHANGES ACTIVITY PATTERN . TEXT FROM 
MODIFICATION : ACTIGRAPHY : WEARING AN 
ACTIGRAPHY WRISTBAND . PARTICIPANTS ARE ASKED TO 
WEAR A WRIST -WORN  ACCELEROMETER FROM VISIT 1 
TO VISIT 6. THE DEVICE RECORDS REST AND ACTIVITY 
PHASES BY MEANS OF AN  ACCELEROMETER , THUS 
ALLOWING CONCLUSIONS TO BE DRAWN ABOUT THE 
SLEEP -WAKE RHYTHM . WE PURSUE AN  ADDITIONAL 
EXPLORATORY GOAL WITH ADDING ACTIGRAPHY : 
SUPPLEMENTAL DATA IN ADDITION TO THE ALREADY 
APPROVED EEG  WITH REGARDS TO THE 
NEUROPHYSIOLOGY OF MEMORY CONSOLIDATION SLEEP AFTER 
40 HZ STIMULATION (COMPARED TO 21H Z AND 
COMPARED TO NIGHTS WITHOUT STIMULATION IN 
BETWEEN ): THE DEVICE  IS WORN ON THE WRIST (LIKE A 
WATCH ), IT IS LIGHTWEIGHT , AND IT DOES NOT NEED TO 
BE RECHARGED DURING THE  SCHEDULED WEARING 
PERIOD . 
7. MOTOR THRESHOLDING  (TEXT FROM 
MODIFICATION ): SINCE THE ORIGINAL DESIGN OF THE 
STUDY , NEW EVIDENCE SUGGESTS AN INTERESTING 
RELATIONSHIP BETWEEN THE EFFECT OF T ACS  AND 
BRAIN EXCITABILITY MEASURED WITH SINGLE PULSE 
TMS.  WE WILL THEREFORE MEASURE CORTICAL 
EXCITABILITY BY PERFORMING MOTOR THRESHOLDING USING SINGLE PULSE  
TMS  (TRANSCRANIAL MAGNETIC 
STIMULATION ) DURING VISIT 2. THE PROCEDURE TAKES 
ONLY A FEW MINUTES , AND ONLY SINGLE PULSES WILL BE 
APPLIED UNTIL A  MOTOR RESPONSE RESULTS AT THE 
HAND (=5 OUT OF 10 EVOKED POTENTIALS OF FIRST 
DORSAL INTEROSSEUS MUSCLE  =50ΜV PEAK -TO-PEAK ). 
8. (PLANNING ) PREGNANCY IS REASON FOR EXCLUSION  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   4 
Template  Version   2.0            2021- 09-09 1.3  ADAPTED  OUTCOMES TO THE VERSION SUBMITTED TO 
THE IRB  (=ADDING AIM 8). 
 
CHANGING TYPOS IN THE SCHEDULE .   
1.4  - EXCLUSION CRITERIA : PSQI  > 5 (INSTEAD OF >6) 
- SESSIONS : 8AM-12PM, 12PM-6PM  
 
 
  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   5 
Template  Version   2.0            2021- 09-09 Table of Contents 
Table of Version Changes  ..................................................................................................................................... 2  
Statement of Compliance  ..................................................................................................................................... 7  
Table of Abbreviations  ......................................................................................................................................... 8  
1. Protocol Synopsis  ..................................................................................................................................... 9  
2. Introduction  ........................................................................................................................................... 12 
2.1. Background Information  .................................................................................................................... 12 
2.2. Scientific Rationale  ............................................................................................................................. 13 
3. Specific Aims  .......................................................................................................................................... 14 
3.1. Aim 1  .................................................................................................................................................. 14 
3.2. Aim 2  .................................................................................................................................................. 14 
3.3. Aim 3  .................................................................................................................................................. 14 
3.4. Aim 4  .................................................................................................................................................. 14 
3.5. Aim 5  .................................................................................................................................................. 14 
3.6. Aim 6  .................................................................................................................................................. 14 
4. Study Design ........................................................................................................................................... 17 
4.1. Treatment Design  ............................................................................................................................... 17 
4.2. Experimental Design  ........................................................................................................................... 18 
4.3. Measurement Design  ......................................................................................................................... 18 
5. Study Participants  .................................................................................................................................. 22 
5.1. Numbers of Participants  ..................................................................................................................... 22 
5.2. Eligibility Criteria  ................................................................................................................................ 22 
5.3. Enrollment/Selection Strategies  ........................................................................................................ 23 
5.4. Strategies for Retention  ..................................................................................................................... 23 
5.5. Matching and Stratification  ................................................................................................................ 23 
5.6. Randomization  and  Concealment  .................................................................................................... 24 
5.7. Blinding  ............................................................................................................................................... 24 
6. Treatment Design: Procedures  .............................................................................................................. 25 
7. Schedule of Activities and Procedures  .................................................................................................. 27 
7.1. Table of Events  ................................................................................................................................... 27 
7.2. Screening  ............................................................................................................................................ 28 
7.3. Enrollment  .......................................................................................................................................... 29 
7.4. Study Visits  ......................................................................................................................................... 29 
7.5. Early Discontinuations  ........................................................................................................................ 31 
7.6. Enrollees May Drop Out  ..................................................................................................................... 32 
8. Statistical Analysis Plans  ................................................................................................................................ 33 
8.1. Strategies that Apply to all the Aims  ....................................................................................................... 33 
8.2 Sample Description ................................................................................................................................... 33 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   6 
Template  Version   2.0            2021- 09-09 8.3 Aim -Specific Plans  ..................................................................................................................................... 33 
8.4 Planned Interim Analyses  ......................................................................................................................... 34 
9. Sample Size Rationale  .................................................................................................................................... 35 
10. Data Capture and Database Management  .................................................................................................. 35 
10.1. Software for Data Capture  ..................................................................................................................... 35 
10.2. Responsibilities for Data Capture and Database Management  ............................................................. 35 
10.3. Study Records Retention  ....................................................................................................................... 35 
11. Collection and Management of Tissue Specimens  ...................................................................................... 36 
Not applicable.  ................................................................................................................................................ 36 
12. Safety Monitoring and Management  .......................................................................................................... 36 
12.1. Risk / Benefit Assessment ...................................................................................................................... 36 
12.2. Assessment of Safety  ............................................................................................................................. 37 
12.3. Unanticipated Problems, Adverse Events, Serious Adverse Events  ...................................................... 37 
12.4. Safety Monitoring  .................................................................................................................................. 40 
12.5. Study Suspension / Early Termination of the Study  .............................................................................. 40 
13. Regulatory, Ethical, and Study Oversight Specifications  ............................................................................ 40 
13.1. Informed Consent Process ..................................................................................................................... 40 
13.2. Study Discontinuation and Closure  ........................................................................................................ 41 
13.3. Confidentiality and Privacy  .................................................................................................................... 41 
13.4. Future Use of Stored Specimens and Data  ............................................................................................ 42 
13.5. Key Roles and Study Governance  .......................................................................................................... 42 
13.6. Safety Oversight ..................................................................................................................................... 42 
13.7. Clinical Monitoring Plan (CMP)  .............................................................................................................. 42 
13.8. Quality Assurance and Quality Control  .................................................................................................. 43 
13.9. Protocol Deviations  ................................................................................................................................ 43 
13.10. Publication and Data Sharing Policy  .................................................................................................... 43 
13.11. Conflict of Interest Policy  ..................................................................................................................... 43 
14.Additional Considerations ............................................................................................................................. 44 
15. References  .................................................................................................................................................... 44 
 
 
    
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   7 
Template  Version   2.0            2021- 09-09 Statement of Compliance  
This study will be conducted as specified in the protocol and in accordance with the International Conference on 
Harmonisation Guidelines for Good Clinical Practice  (ICH E6) and the Code of Federal Regulations on the Protection 
of Human Subjects  (45 CFR Part 46).  
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the Institutional Review Board (IRB) for review and approval.  Approval of both the protocol and the consent form 
must be obtained before any participant is enrolled.  Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study.  In addition, all changes to the consent form 
will be IRB- approved; a determination will be made regarding whether a new consent needs to be obtained from 
participants who provided consent, using a previously approved consent form.  
If required by the IRB, the master protocol document, informed consent form(s), recruitment materials, and all 
participant materials will be submitted to the Scientific Review Committee  (SRC) prior to IRB review 
(research.unc.edu/clinical -trials/src) . 
The statistical analysis plans will be consistent with guidance  in CONSORT Statement [1] or STROBE Statement [2], 
ICMJE recommendations [3], the 2016 and 2019 statements of the American Statistical Association [4,5], and recommendations in Nature [6,7].
*  
All personnel involved in the conduct of this study have completed human participant s protection training.  
 
 
     
 
 
 
*  [1]   www.consort -statement.org   
   [2]  www.strobe -statement.org   
   [3]  www.icmje.org   
   [4]  Wasserstein RL, et al. (2016), The ASA's Statement on p -Values, The American Statistician, 70:2, 129 -133  
   [5]  Wasserstein RL, et al. (2019), Moving to a World Beyond p < 0.05, The American Statistician, 73:sup1, 1- 19  
   [6]  Amrhein, et al. (2019) Scientists rise up against statistical significance, Nature 567, 305- 307  
   [7]  Editorial (2019) It’s time to talk about ditching statistical significance: Looking beyond a much used and abused measur e 
          would make science harder, but better. Nature 567, 283- 283.  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   8 
Template  Version   2.0            2021- 09-09 Table of A bbreviations  
AE / SAE  adverse  event  / serious adverse event  
CFR U.S. Code  of Federal  Regulations  (www.eCFR.gov)  
CI confidence  interval  
CIOMS  Council  for International  Organizations  of Medical  Sciences  (cioms.ch)  
CoC certificate of confidentiality  
CONSORT  Consolidated  Standards  of Reporting  Trials  (www.consort -statement.org)  
CRF case  report  form  
CRO  contract  research  organization  
CSCC  UNC C ollaborative  Studies  Coordinating  Center   (sites.cscc.unc.edu/cscc)  
CT.gov  ClinicalTrials.gov website  
DCC data  coordinating  center  
DSMB  data  and safety  monitoring  board  
eCRF  electronic  case  report  form  
eCTD  electronic  common  technical  document  
EEG Electroencephalography /electroencephalogram  
DOH!  I need  to delete  this example  term  (and  others  not used in this protocol ) from  this table  
FDA U.S. Food  and Drug  Administration    (www.fda.gov)  
GCP good  clinical  practice  
HIPAA  U.S. Health  Insurance  Portability  and Accountability  Act   (www.hhs.gov/hipaa)  
ICF informed  consent  form  
ICH International  Council  for Harmonization    (www.ich.org)  
ICMJE  International  Committee  of Medical  Journal  Editors    (www.icmje.org)  
IDE investigational  device  exemption  
IDS UNC Investigational Drug Services  (uncids.web.unc.edu)  
IND investigational  new  drug  application  
IRB institutional  review  board  
MAR  missing  at random  criterion  
MCAR  missing  completely  at random  criterion  
MNAR  missing  not at random  criterion  
MICE  multiple imputation by chained equations  
MOP  manual  of procedures  
MPD  master  protocol  document  
N number  of enrolled  participants  
NDA  new  drug  application  
OCT UNC Office of Clinical Trials  (research.unc.edu/clinical -trials)  
OHRP  Office  for Human  Research  Protections  
PHI protected  health  information  
PI principal  investigator  
PRC UNC Oncology Protocol Review Committee    (UNClineberger.org/protocolreview)  
QA quality  assurance  
RCT randomized controlled trial  
REDCap  Research Electronic Data Capture system  
SD standard  deviation  
SE standard  error  
SOP standard  operating  procedures  
SRC UNC Scientific Review Committee    (research.unc.edu/clinical -trials/src)  
STROBE  Strengthening  Reporting  of Observational  Studies  in Epidemiology    (www.strobe -statement.org)  
tACS  Transcranial Alternating Current Stimulation  
TraCS  N.C. Translational and Clinical Sciences Institute    (tracs.unc.edu)  
UNC  The University of North Carolina  
UNCH  UNC Hospitals  
 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   9 
Template  Version   2.0            2021- 09-09 1. Protocol Synopsis 
Title  Effects of Transcranial Alternating Current Stimulation (tACS)  
on Memory Recall and Sleep -EEG in Healthy Elderly Participants 
(SUPERCHARGE)  
Study Description  The purpose  of this clinical trial is to investigate the feasibility and eff icacy  
of non -invasive transcranial alternating current stimulation (tACS) at 
gamma frequency in enhancing memory recall and modulating sleep  
network dynamics measured by at -home electroencephalography (EEG) 
in healthy elderly people . Eligible participants will first collect sleep  EEG 
at home for one night  to acclimate to the data collection during sleep . 
Participants are then randomized into first undergoing either gamma -
tACS or control control  tACS. Stimulation is administered in the lab during 
a cognitive testing  battery that includes memorizing items. After a night 
of sleep with EE G at home, participants return to the lab the following day 
to measure memory recall. Memory recall is tested again by telephone 
five days later. This sequenc e of encoding during stimulation  in the lab , 
sleep  EEG at home for one night, and memory recall is then repeated for 
the other stimulation condition about a  week later. An acigraphy watch 
(accelerometer) is worn during the whole study period.  
Specific Aims  
(objectives)  Aim 1 : To establish acceptability of cognitive testing during tACS in 
healthy elderly participants . 
Aim 2:  To investigate the effect of a single session of gamma -tACS 
(compared to control  tACS) on verbal memory (a) and associative me mory 
(b) performance during stimulation , on the day after stimulation and after 
five days.  
Aim 3: To establish feasibility of at -home use of a single -channel EEG 
device during one night  (a) and acceptability during three nights (b ).  
Aim 4: To investigate the effect of a single session of gamma -tACS  
(compared to control  tACS) on the amount of sleep spindles (a) and slow 
wave sleep ( b) occu rring during the night after the intervention.  
Aim 5: To see if there is a correlation between memory recall 
performance and sleep EEG features (especially spindles, slow waves).  
Aim 6: To investigate the effect of a single session of gamma -tACS 
(compared to control  tACS) on a letter  fluency ta sk (a ), executive 
functioning (Stroop Test  (b), Trail Making Test  (c)) and attention 
(Attentional Performance, TAP  (d)). 
Aim 7:  To see if the  motor  activity pattern (measured by actigraphy) 
changes after stimulation/type of stimulation.  
Aim 8:  To investigate if there is a relationship between the brain 
excitability derived from the subjective effect  of tACS and the motor 
threshold measured by TMS.  
Target Population  Inclusion Criteria   
• >50 years old  
 
Exclusion Criteria  
• Implanted device or metal in head (including cochlear implant 
or other hearing aid), cardiac pacemaker or any other 
powered medical device  
• Known neurological disease from history (epilepsy, sleep 
disorder (insomnia, sleep apnea, restless legs syndrome, 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   10 
Template  Version   2.0            2021- 09-09 parasomnia), stroke or transitory ischemic attack, cognitive 
impairment, neurodegenerative disease (for example 
Alzheimer’s disease, Parkinson’s disease or amyotrophic 
lateral sclerosis), immune -mediated disease of the central 
nervous system, chronic infec tious brain disease, brain 
tumor, traumatic brain injury with loss of consciousness 
and/or intracranial bleeding, chronic pain with the need for 
daily analgesic use)  
• Positive screening for epilepsy (questionnaire)  
• Pathological Montreal Cognitive Assessment (MoCA <26/30 points)  
• Brain surgery in the past (lifetime)  
• Known psychiatric dis order  from history (schizophrenia 
(lifetime), obsessive compulsive disorder (OCD; lifetime), 
borderline personality disorder (lifetime), anxiety disorder 
(lifetime), bipolar disorder (lifetime), psychosis (lifetime), 
eating disorder (lifetime), depression (within the last th ree 
months)  
• Positive screening for anxiety disorder (GAD -7 ≥10/21 points) 
or positive screening for depression (PHQ -9 ≥5/27 points)   
• Known other relevant medical condition from history 
(moderate to severe chronic obstructive pulmonary disease 
(COPD), abnormal kidney function (defined as estimated 
Glomerular Filtration Rate <60ml/min), current liver disease (defined as hepatitis and/or liver cirrhosis), cancer, diabetes 
mellitus, cardiac disease (heart failure, myocardial infarct, 
atrial fibrillation and revascularization – all within the last 
three months)  
• Working in night shifts or going to bed after midnight on 3 or more nights per week  
• Positive screening for sleep disorder (PSQI > 5/21 points)  
• Psychotropic treatment or illegal drugs (including cannabis) within the last three months 
• I
ndication for alcohol use disorder: AUDIT score (Alcohol  Use 
Disorders Identification Test; screening for unhealthy alcohol 
use) ≥7 for females and for males ≥ 65 years or ≥8 for males 
<65 years  
• N ot willing to abstain alcohol at least 24 hours before each 
study visit  
• Women who want to become pregnant, are pregnant, plant to 
seek or are seeking fertility treatment  
 
Reason for immediate early termination of participation 
• Epileptiform  activity in 128 -channel EEG on the first day  
 
Numbers of Enrollees  This pilot study require s n = 28  participants who  complete all aspects of 
the protocol.  Participants are recruited and enrolled until this target is 
reached. We anticipate screening up to 100 participants  and enrolling up 
to 50 participants .  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   11 
Template  Version   2.0            2021- 09-09 Intervention  This is a  single -center prospective interventional  control controlled cross -
over pilot study .  
The intervention consists of the application of tACS stimulation in the 
gamma -frequency range during approximately one hour of cognitive  
testing.  
Outcome Measures  Aim 1 : 
 Cognitive testing during tACS  completed in >80% of participants . 
Aim 2:  
Participants will memorize 15 words ("Rey Verbal Learning Test" , (a)) and 
8 word -pairs (associative verbal memory, (b)) during gamma- tACS and  
control tACS. They will be required to recall the words after a short delay 
on the same day, on the day after and after 5 days ("ultra -delayed recall"). 
The number of correctly remembered words (a) and word -pairs (b) will be 
recorde d. 
Aim 3: 
Feasibility (a)  will be considered feasible if the device has been worn for 
at least 4 hours during the first night for >/= 80% of participants.  
Acceptability (b) will be considered as given if the device has been worn 
for at least 4 hours during each of the three nights in >/=80% of 
participants. 
Aim 4:  
Amount of sleep spindles (a) and slow wave sleep (b) during sleep 
recording.  
Aim 5:  
Exploration of c orrelation between memory recall performance and sleep 
EEG features (especially spindles, slow waves) . Difference  in recall scores 
(verum versus sham tACS) will be correlated with differences  in sleep EEG 
features (verum versus sham tACS).  
Aim 6:  
For (a) the number of correct words, of perseverations and of rule 
breaks will be calculated. For (b) and (c)  time for test completion and 
errors will be calculated. For (d) percentile ranks for the following 
subtests will be calculated: Alertness, Go/NoGo, Divided Attention, 
Visual Scanning.  
Aim 7:  
Exploration of correlation between amount of motor activity/inactivity 
phases (measured by actigraphy watch) and stimulation versus no 
stimulation as well as gamma- versus control  stimulation.  
Aim 8:  
Exploration of correlation between the TMS motor threshold and the 
maximal tolerated amplitude (according to the subjective symptoms) for 
tACS.  
Statistical Analysis Plans  
for Each Aim  Aim 1 : Proportion (percentage and 95% confidence interval) of 
participants with  completed cognitive testing during stimulation study 
session.  
Aim 2 : 
Comparison of memory and associative  testing after stimulation and 
sham on individual and group level using ANCOVA.  
Aim 3 : 
Proportion  (percentage, 95% confidence interval) of participants with  at 
least four hours of EEG -data in the first  night  (a).Proportion (percentage, 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   12 
Template  Version   2.0            2021- 09-09 95% confidence interval) of participants who successfully collected at 
least four hours of EEG for all three  study nights  (b). 
Aim 4 : 
Comparison of sleep spindles (a) and slow wave sleep (b)  derived from 
sleep EEG for verum versus control  tACS using ANCOVA.  
Aim 5 : 
Exploratory investigation of correlations (Pearson’s) between stimulation 
induced changes in memory recall performance  and sleep EEG features.  
Aim 6 : 
Comparison of test results after stimulation and sham on individual and 
group level using ANCOVA.  
Aim 7:  Exploratoy  investigation of correlations (Pearson’s) between  
changes in motor activity pattern  before and after stimulation.  
Aim 8: Exploratory investigation of a correlation (Pearson’s) between the level of the TMS motor threshold and the tolerated tACS level (lower level 
from 21  Hz and 40  Hz, based on subjective symptoms ).  
Study Duration  1 year  
Participation Duration  2 weeks  
Enrollment Duration  6 months  
 
  
2. Introduction 
2.1.   Background Information  
The decline of cognitive functions, especially memory, is a common complaint, both during the normal ageing 
process and in dementia  (1): More than half of the population will probably face such symptoms in their second 
half of life.  
 
Parallel to cognition, sleep architecture changes in older age , including a  reduction of slow wave sleep (for a review 
see (2)). Given the importance  of sleep for the consolidation of memory (for a review see (3) and (4)) and its role in 
reducing cellular waste (including amyloid, the pathological hallmark of Alzheimer’s disease) via the glymphatic system (5), it seems plausible  that a deterioration of sleep in older individuals partly explains a worsening of memory 
functions.  
 Despite the importance of the problem, there is still a lack of effective measures against cognitive decline in ageing 
individuals.  
 
However, advances in neuroscience within the last few years have given us an increasingly detailed understanding of the oscillations of brain activity in neural circuitries associated with cognitive processes, offering  possibilities of 
influencing them.  
 Transcranial alternating current stimulation (tACS) is an established, safe way to non -invasively modulate 
oscillations in neuronal networks and thus potentially  restore and improve the associated cognitive functions  (for a 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   13 
Template  Version   2.0            2021- 09-09 recent review of applying tACS to improve c ognition in various contexts see (6), for tACS to improve memory in 
healthy adults see (7) ).  
 
  
2.2.   Scientific Rationale  
This controlled cross -over pilot study will be used to prepare for a full- scale RCT in patients with mild cognitive 
impairment by investigating feasibility as well as acceptability and adherence of the study procedures  in a sample 
of n=28 healthy elderly adults . Any effect on memory performance and sleep EEG will be documented  but is not a 
requirement for the development of an RCT.  We include people over 50 years of age because memory problems 
and neurodegenerative diseases (specifically Alzheimer's Disease) occur in the second half of life. The exclusion criteria are designed to ensure that people are not cognitively impaired by a disease of the brain or other impairment of bodily functions. In addition, we exclude contraindications to tACS.    The pilot study serves as a basis for the application of the technique in specific patient groups, in particular those with mild cognitive impairment.  
  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   14 
Template  Version   2.0            2021- 09-09 3. Specific Aims  
 
3.1.  Aim 1  
To establish acceptability of cognitive testing during tACS in healthy elderly particpants. The threshold is set 
to 80% of participants.  
 
3.2.  Aim 2 
Evaluation of an effect of a single session of gamma-tACS on memory (a) and associative memory  (b) 
performance compared with control  tACS. The estimand of interest is the comparison of the individual 
results of the memory  tests at the individual and at the group level  (paired t-test or a non -parametric test, 
respectively) . for delayed (immediately after stimulation) and ultra -delayed recall (after a night of sleep as 
well as after 5 days ).  
 
3.3.  Aim 3  
Feasibility (a) and acceptability (b) of an ambula tory single -channel EEG device. The estimands  of interest 
are the proportion of participants with at least four hours of recording in  the first  night (a) and the 
proportion of participants with three  nights  of at least 4 hours of EEG data  (b). 
 
3.4.  Aim 4 
The comparison of specific sleep EEG features , i.e. sleep spindles (a) and slow wave sleep (b), which are 
both  prominently associated with cognitive functioning, especially memory processes , after each 
stimulation condition . Comparison will be on individual and on group level (via t -test or a non -parametric 
test, respectively).  
 
3.5.  Aim 5  
To investigate whether there is  a correlation between the effects of tACS (versus control control tACS) on 
memory recall  and memory -associated sleep EEG features (especially amount of sleep spindles and slow 
wave sleep)  on an exploratory level.  
 
3.6.  Aim 6  
To investigate the effect of a single session of gamma- tACS (compared to control control tACS) on different 
cognitive functions, i.e. a letter  fluency task (a), executive functioning (Stroop Test (b), Trail Making Test (c)) 
and attention (Attentional Performance, TAP (d)). These tests will be performed during stimulation and on 
the day after stimulation , and comparison will be calculated on the individual and on the group level (paired 
t-test or non -parametric test, respectivel y). For (a) the number of correct words, of perseverations and of 
rule breaks will be calculated. For (b) and (c) time for test completion and errors will be calculated. Fo r (d) 
percentile ranks for the following subtests will be calculated: Alertness, Go/NoGo, Divided Attention, Visual Scanning.  
 
3.7 Aim 7  
To investigate whether there is a correlation between the effects of stimulation (in general) and/or the 
specific type of stimulation (gamma versus control) on the  motor  activity level measured by an actigraphy 
watch.  
 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   15 
Template  Version   2.0            2021- 09-09 3.8 Aim 8  
To investigate if there is a relationship between the brain excitability derived from the subjective 
effect  of tACS  and the motor threshold measured by TMS.  
 
 
Specific Aims with Measures and Aim -Specific Statistical Analysis Plans  
 
Specific  
Aim Outcomes  
Measures  Population Parameters 
to be Estimated 
(“Estimands”)  Statistical  
Estimators 
Aim 1:  
To investigate 
the feasibility of 
cognitive testing 
during tACS  Fraction o f participants who complete  both  stimulation and cognitive 
testing sessions  Proportion of participants 
with completed 
stimulation - and testing -
protocol  Observed proportion 
and 95% C.I.  
Aim 2:  
Evaluate the effect of gamma -
tACS on memory 
testing  Results of delayed ultra -delayed verbal memory and associative verbal 
memory recall (after stimulation, day after stimulation  and 5 days after 
stimulation ) for gamma versus control tACS   Memory recall in Rey 
Auditory Verbal Learning Test  (a) and a word  
association test ( b); 
amount of words and 
word -pairs remembered 
after stimulation, on day after stimulation  and 5 
days later will be recorded  
 Comparison 
between results after  
stimulation and 
sham on individual and group level (mean differences, 
regression 
coefficients, 
components of 
variance)  
Aim 3: 
Investigate 
feasibility (a) and 
acceptability (b) 
of wearable device (single-
channel EEG 
during the night)  Fraction of partici pants  wearing the device on (a) the first and (b) all 
three night s planned according to the protocol.  
 Proportion of participants 
having worn the device 
during (a) the first and (b) 
all three nights for at least four hours  each night  Observed proportion 
and 95% C.I.  
Aim 4:  
Evaluate the effect of gamma -
tACS on sleep spindles (a) and 
slow wave sleep 
(b) compared to 
sham stimulation Amount of sleep spindles (a) and slow wave sleep (b) after tACS -
stimulation and control stimulation.  
 Differences (individual 
level and means) of sleep spindle frequency 
(maximum number per 
hour) and slow wave 
activity (maximum 
minutes of slow wave sleep per hour)  Comparison 
between results after gamma -tACS 
and control tACS on 
individual and group 
level (mean differences, components of 
variance , regression 
coefficients ) 
Aim 5:  
To investigate  
whether there is a correlation 
between 
memory recall 
and sleep EEG  Memory and associative memory recall performance ; EEG features (as 
for aim 4) Correlation between 
changes in memory recall 
and sleep EEG (amount of 
spindles and slow wave 
sleep) for gamma - versus 
control tACS  Exploratory 
investigation of 
correlations 
(Pearson’s) between 
stimulation induced 
changes in memory 
recall performance 
and sleep EEG 
features  
Aim 6: To 
investigate the effect of 
stimulation  on 
different 
cognitive 
functions, i.e. a 
letter  fluency 
task (a), 
executive 
functioning 
(Stroop  Test (b), 
Trail Making Test 
(c)) and attention Effect of tACS and control stimulation on cognitive testing during and on 
the day after stimulation.  For (a) the number of 
correct words, of 
perseverations and of rule 
breaks will be calculated. 
For (b) and (c) time for test completion and errors will 
be calculated. For (d) 
percentile ranks for the following subtests will be 
calculated: Alertness, 
Go/NoGo, Div ided 
Attention, Visual Scanning  
 Comparison 
between results 
after stimulation and 
sham on individual and group level (mean differences, 
regression 
coefficients, components of 
variance)  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   16 
Template  Version   2.0            2021- 09-09 (Attentional 
Performance, 
TAP (d)) 
Aim 7: To 
investigate whether there is a correlation 
between motor 
activity level and stimulation  Effect of stimulation on motor activity level  Correlation between 
changes in the amount of motor activity the day after stimulation versus 
the day before; (a) after 
stimulation in general and (b) after gamma - versus 
control stimulation.  Exploratory 
investigation of correlations 
(Pearson’s) between 
the day before and after the (respective) 
stimulations.  
Aim 7: To 
investigate whether there is 
a correlation 
between the TMS motor 
threshold and 
the tolerated tACS amplitude 
(based on 
subjective 
symptoms)  Association between TMS motor threshold and symptoms from tACS  Correlation between the 
level of TMS motor threshold and the highest 
tolerated tACS level (21Hz 
and 40Hz, lower value).  Exploratory 
investigations of correlations 
(Pearson’s) between 
the measures (% and  
mA).  
 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   17 
Template  Version   2.0            2021- 09-09 4. Study Design  
 
This is a single -center prospective interventional pilot study with a controlled crossover -design.  Each participant is 
exposed once to the intervention (tACS) and once to the control  intervention ( control  tACS) to allow not only an 
interindividual but also an intraindividual comparison of outcomes under both conditions. Thus, each participant 
can serve as their  own control.  
 First, an online prescreening  (in REDCap)  is performed , where basic eligibility information and informed consent for 
a screening by telephone is  obtained. If, in the subsequent phone screen, inclusion/exclusion criteria are met and 
the participant provide verbal consent,  a meeting on site (UNC Chapel Hill) will be  arranged , where participants  will 
sign informed consent and undergo baseline assessments (day 1 ). Afterwards, p articipants will receive the single-
channel EEG for the following night (night 1). The next  day (day 2), the in tervention ( gamma -tACS  or control tACS ) 
during cognitive testing  will take  place . During the following  night ( night 2) the EEG will be  worn again  for recording 
of sleep EEG at home . The follow -up cognitive testing will be  scheduled for t he day after (d ay 3) , and again for the 
fifth day after stimulation (memory recall by telephone).  
This procedure will be  repeated for the respective other intervention (gamma -tACS or control tACS ) one week ( 5-9 
days) later. Each participant will be wearing an actigraph (accelerometer wristband) during the study period. Additionally, we will perform motor thresholding by TMS on day 2. Additionally, TMS motor thresholding will take 
place during day 2.  
 
Centralized s ervices are not used. All d ata (including baseline assessment, cognitive  testing results) are  stored in a 
REDCap  database . 
 
4.1.  Treatment Design  
Memory – as cognition in general – is based on synchronous oscillatory activity within and across  neuronal 
network s. Neuronal network activity can be modified  via non -invasive brain stimulation. Transcranial alternating 
current stimulation (tACS) is a well- established  and safe form of non -invasive stimulation. Stimulation frequency 
and location is chosen to engage the neuronal networks of interest as a function of the psychological constructs investigated in a given study. Here, we will use gamma -frequency -tuned tACS targeting  bilateral temporal lobes 
during cognitive testing including a verbal memory task, with ultra-delayed recall on the day after the stimulation  
and after five days .  
There is evidence for the improvement of episodic memory throu gh the use of tACS in the gamma -frequency range 
in healthy participant s ((8), (9), (10), (11)). We favor the temporal lobes over other locations for stimulation because  
gamma band brain activity occurs in temporal neocortex and hippocampus, both during memory encoding in the awake state and during memory consolidation in slow wave sleep ( (12), (13), (14)). 
 We decided for an alternative frequency (21 Hz) as  control intervention  in order to match the side effects associated 
with bilateral tempral stimulation .  The tACS amplitude will be titrated individually (evaluation of side effects; start 
with 2mA peak -to-peak, -0.25mA until side effects tolerable for at least 1 hour, respective testing for 40 Hz and for 
21 Hz, lower well- tolerated amplitude is being administered during tasks).  
 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   18 
Template  Version   2.0            2021- 09-09 4.2.   Experimental Design  
This is a controlled cross -over study. Participants will be  randomly  allocated  to the respective sequence (first tACS, 
then control  stimulation – vice versa) via simple randomization , i.e. based on a single sequence of random sequence 
numbers generated by computer .  
 
4.3.   Measurement Design  
Table 1.  Variables of interest: their occasions of evaluation, their uses for the aims, their roles in the study  
Variables within  
Domain s Scale1 Occasions2  Aims3 Main Roles 
Identifiers      
Participant ’s unique  ID Nominal  All All Identifier  
Intervention  (A or B)* Binary  E All Identifier  
General  Profile      
Age  Decimal yrs  S All Screening, 
covariate uses  
Implanted 
device /hearing aid  Binary  S All Screening  
Cardiac pacemaker  Binary  S All Screening  
Willingness to abstain 
from alcohol ≥24h 
before visit  Binary  S All Screening  
Known neurologic 
diseases  Binary  S All Screening  
Known psychiatric 
diseases  Binary  S All Screening  
Known other medical 
conditions  Binary  S All Screening  
Brain surgery in the past  Binary  S All Screening  
Night shifts, bed after 
midnight  Binary  S All Screening  
Use of illegal drugs  Binary  S All Screening  
Sex Categorical  0 All Covariate uses  
Racial/ethnic categories  Categorical  0 All Covariate uses  
Education  Categorical  0 All Covariate uses  
Living conditions  Categorical  0 All Covariate uses  
Work status  Categorical  0 All Covariate uses  
Clubs/social 
organizations  Binary  0 All Covariate uses  
Sports  Binary, categorical  0 All Covariate uses  
Social contacts  Binary, categorical  0 All Covariate uses  
Media consumption  Categorical  0 All Covariate uses  
Concomitant 
medications list  Nominal  0 All Covariate uses  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   19 
Template  Version   2.0            2021- 09-09 Caffeine consumption  Binary, nominal, dL  0 All Covariate uses  
Alcohol consumption  Binary, nominal, dL  0 All Covariate uses  
Smoker  Binary, yrs, cig/d  0 All Covariate uses  
Questionnaires      
Sleep Quality 
Assessment PSQI  (15) Ordinal 0 -21 0 All Screening  
Patient Health 
Questionnaire -9 (16) Ordinal 0 -27 0 All Screening  
General Anxiety 
Disorder -7 (17) Ordinal 0 -21 0 All Screening  
Alcohol Use Disorders 
Identification  Test (1-3) 
(18) Ordinal 0 -18 S All Screening  
AD8 Dementia Screening  
(19) Ordinal 0 -8 0 All Screening  
Montreal Cognitive 
Assessment  (20) Ordinal 0 -30 0 All Screening  
Epilepsy Screening  (21) Binary  0 All Screening  
Handedness 
Questionnaire  (22) Laterality Index  0 All Covariate uses  
Behavioral Inhibition and 
Behavioral Activation 
Self Report Scales (BIS/BAS)  (23)  Ordinal, 4 subscales:  
BIS (7 to 28)  
BAS drive (4 -16) 
BAS fun -seeking (4 -16) 
BAS reward (7 -20) 0 All Covariate uses  
Basic Sleep Habits  hh:mm; hours/min  0 All Covariate uses  
Stimulation conditions      
Epileptiform activity in 
EEG Binary  0 All Early 
termination of study 
participation  
     
Karolinska  Sleepiness 
Scale  (24) Ordinal 1 -10 D1A, D2A,  
D1B, D2B  Aim 2  Covariate use  
PANAS  (Positive and 
Negative Affect 
Schedule)  (25) Ordinal 20 -100 D1A, D2A,  
D1B, D2B  Aim 2  Covariate use  
Sleep quality night 
before  Categorical (nominal)  D1A, D2A,  
D1B, D2B  Aim 2  Covariate use  
Cognitive  testing      
Completed  Binary  D1A, D2A,  
D1B, D2B  Aim 1  Primary 
outcome  
Delayed and u ltra-
delayed recall from  
Rey Auditory Verbal Learning Test  (RAVLT ) 
(26) and from word  Ratio  
(number of correct words ); number of correct 
words for trials 1 -5 (=learning), for trial 6 
(“interference”) and for trial 7 (“recall”); D1A, D2A, 
PA, D1B,  
D2B, PB Aim 2 , 
Aim 5  Primary 
outcome  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   20 
Template  Version   2.0            2021- 09-09 association test ; RAVLT 
encoding  number of confabulations and perseverations 
in total)  
Time from encoding of 
RAVLT and word  
association test to 
delayed and ultra -
delayed recall  Interval (hh:mm)  D1A, D2A, 
PA, D1B, 
D2B, BP Aim 2  Covariate use  
Time from encoding of 
word association test to 
delayed and ultra -
delayed recall  Interval (hh:mm)  D1A, D2A, 
PA, D1B, D2B, BP  Aim 2  Covariate use  
     
RAVLT  
 Ratio  
(number of correct words for trials 1 -5 
(=learning), for trial 6 (“interference”) and for trial 7 (“recall”) ; number of confabulations and 
perseverations in total ) D1A, D1B  Aim 2   Covariate use  
Word association test  Ratio  
(number of correct words for trials 1 -4) D1A, D1B  Aim 2  Covariate use  
Letter  Fluency (28) Ratio  
(number of correct words, number of 
perseverations and number of rule breaks)  D1A, D2A,  
D1B, D2B  Aim 6  Secondary 
outcome  
Stroop Color and Word 
Test (29) Interva l (sec),  
ratio  (errors)  D1A, D2A,  
D1B, D2B  Aim 6  Secondary 
outcome  
Trail Making Test A and B 
(30) Interval  (sec),  
ratio  (errors)  D1A, D2A,  
D1B, D2B Aim 6  Secondary 
outcome  
Test of Attentional 
Performance  (TAP ) (31) Interval, ratio  
(Alertness: Percentile rank of median reaction 
time for correct responses, percentile rank of standard deviation ; Go/NoGo: Percentile rank 
of median reaction time for correct responses, percentile rank of standard deviation, percentile rank of errors;  D ivided Attention: 
Percentile rank of median reaction time for correct responses, percentile rank of standard deviation, percentile rank of errors, percentile rank of omissions; Visual S canning: Percentile 
rank of median of critical and non- critical, 
respective standard deviation, omissions)   D1A, D2A,  
D1B, D2B  Aim 6  Secondary 
outcome  
Sleep EEG      
First night with ≥ 4 hours 
of recording  Binary (hh:mm)  N1 Aim 3  Primary 
outcome;  
 early 
termination of study 
participation if 
<4 hours  
EEG worn for ≥4h hours 
in 3/3 nights  Binary (nights)  N1, N2A, 
N2B  Aim 3  Primary 
outcome  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   21 
Template  Version   2.0            2021- 09-09 Sleep latency  Minutes  N1, N2A, 
N2B  Aim 4 , 
Aim 5  Covariate use  
Sleep efficiency  % N1, N2A, 
N2B  Aim 4 , 
Aim 5  Covriate use  
Sleep spindles, slow 
wave sleep  Amount/hour  N1, N2A, 
N2B  Aim 4 , 
Aim 5  Primary 
outcome  
Subjective tolerability of 
headband  Binary, nominal  N1, N2A, 
N2B  Aim 3  Exploratory use  
Actigraphy      
Motor activity/24 hours, 
resting time for sleep  %, hours  N2A, D2A, 
N2B, D2B  Aim 7 Exploratory 
outcome  
Thresholding      
TMS motor threshold  % MSO (maximal stimulator output)  D2A  Aim 8  Exploratory 
outcome  
tACS thresholding  mA (lower value of 21 Hz and 40 Hz)  D2A  Aim 8  Exploratory 
outcome  
Safety Monitoring      
AEs and SAEs 
documentation  Events  All All Safety 
monitoring  
   
1 Units of measurement or the scale . 
  2 Occasions of evaluation  or retrieval :   
S = Screening  
0 = Enrollment and Baseline  
N1 = Night 1  
D1A  = Day 1 in Intervention A  
N2A  = Night 2 in Intervention A  
D2A  = Day 2 in Intervention A  
PA = Phonecall in Intervention A  
D1B  = Day 1 in Intervention B  
N2B  = Night 2 in Intervention B  
D2B  = Day 2 in Intervention B  
PB = Phonecall in Intervention B  
 
  3 The s pecific aims in which the variable will play a role in data analyses.  
  4 Uses: assess medication adherence, mediation analyses, and exploratory  analyses  
 
 * Intervention :   
  A = tACS   
  B = control  stimulation  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   22 
Template  Version   2.0            2021- 09-09 5. Study Participants 
5.1.  Number s of Participants  
 5.1.1.  Number to be screened :  N ≤ 100  
 5.1.2.  Number to be enrolled:    N ≤ 50 
The sample size is 28 participants in the final dataset , i.e. the participants who completed all the visits for the 
primary outcomes, i.e. Visits 1, 2, 3, 4, 5, 6, 7 (including the three nights with EEG ). However, to ensure that 28 
participants complete the experiment, we conservatively estimate to screen 100 participants and to enroll 50 
participants as a ceiling for the sake of IRB approval. The motivation for the sample size of 28 participants is the 
following power analysis: power analysis: dz = 0.5, 1 -beta = 0.80, alpha = 0.05 . Participants who drop -out or have 
missing data will be replaced.   
Recruitment takes place in the general population.  
 
5.2. Eligibility  Criteria  
Participants have to complete a set of questions (in REDCap) during the screening process. They  will be instructed 
to consume no alcohol and no more caffeine than usual 24 hours before each study visit.  
 
 5.2.1.  Inclusion Criteria   
In order to be eligible to participate in this  study, an individual must meet the following criterium : 
•  >50 years old  
 
 5.2.1.  Exclusion Criteria   
Any individual who meets one or more of the following criteria will be excluded from participation: 
• Implanted device or metal in head (including cochlear implant or other hearing aid) , cardiac pacemaker  
or any other powered medical device  
• Known neurological disease  from history (e pilepsy, sleep disorder (insomnia, sleep apnea, restless legs 
syndrome, parasomnia), stroke or transitory ischemic attack, cognitive impairment, neurodegenerative 
disease (for example Alzheimer’s disease, Parkinson’s disease or amyotrophic lateral sclerosis), immune -mediated disease of the central nervous system, chronic infectious brain disease, brain tumor, 
traumatic brain injury with loss of consciousness and/or intracranial bleeding, chronic pain with the need for daily analgesic use ) 
• Positive screening for epilepsy (questionnaire)  
• Pathological Montreal Cognitive Assessment (MoCA <26/30 points)  
• Brain surgery in the past  (lifetime)  
• Known psychiatric dis order from history (schizophrenia ( lifetime), obsessi ve compulsive disorder (OCD; 
lifetime), borderline personality disorder ( lifetime), anxiety disorder (lifetime), bipolar dis order 
(lifetime), psychosis (lifetime), eating disorder (lifetime), depression ( within  the last three months)  
• Positive screening for anxiety disorder (GAD -7 ≥10/21 points) or positive screening for depression (PHQ -
9 ≥5/27 points)   
• Known other relevant medical condition  from history (moderate to severe chronic obstructive 
pulmonary disease (COPD), abnormal kidney function (defined as estimated Glomerular Filtration Rate <60ml/min), current liver disease (defined as hepatitis and/or liver cirrhosis), cancer, diabetes mellitus, cardiac disease (heart failure, myocardial infarct, atrial fibrillation and revascularization – all within the 
last three months)  
• Working in night shifts  or going to bed after midnight  on 3 or more nights per week  
• Positive screening for sleep disorder (PSQI > 5/21 points)  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   23 
Template  Version   2.0            2021- 09-09 • Psychotropic treatment or i llegal drugs (including cannabis) within the last three months  
• Indication for alcohol use disorder: A UDIT score ( Alcohol  Use Disorders Identification Test; screening for 
unhealthy alcohol use)  ≥7 for f emales and for males ≥ 65 years or ≥8 for males <65 years  
• Not willing to abstain alcohol at least 24 hours before each study visit  
• Women who want to become pregnant, are pregnant, plant to seek or are seeking fertility treatment  
 
5.3.  Enrollment/Selection Strategies  
 5.3.1.   Prospective Recruitment  
We will advertise the study directly to the public on websites such as ClinicalTrials.gov, studypages.com,  Research 
For Me, frohlichlab.org and Carolinaneurostimulation.org. We will have contact information and a summary of the 
clinical trial posted on the Frohlich Lab Facebook and Twitter pages. We will  also be launching a Facebook  or 
Instagram  advertisement  to identify potential participants . Furthermore, we will also be using the UNC Mass email 
and department listserv to send out an email containing the advertisement. In addition, we will post fliers  senior 
living communities. We have previously recruited about 50 participants from an identical population within 3 
months.  
We will send unencrypted emails to facilitate the initial contact to potential participants. Medical information is never requested per email. All medical information is recorded through HIPAA conform Zoom meetings and REDCap surveys.  
The advertisement  will include a link to a brief pre screening survey on  RED Cap to help identify participants. 
Interested individuals can then either visit the specified website and complete an online screening survey on 
REDCap  or call or email to register for a telephone prescreening. All participant identifiers will be stored in REDCap  
and password encrypted tables stored on UNC servers until recruitment is over. When recruitment is over, all 
patients who do not consent or are not eligible for participation in the study will have their responses permanently deleted.  
Our retention strategy includes a payment schedule of two times $50 per participants . Thus, completion of the 
study will result in a financial compensation of $100 . 
  
 5.3.2.  Screen Failures     
In the case that a participant enrolls in the trial and the screening reveals that they do not meet study criteria, the 
study personnel completing the interviewing process will clearly explain why the participant  does not meet criteria. 
If a time -sensitive criterion is not met, re-screening may occur at a later time. In the worst case, we expect only 
~25%  of those interested to be eligible.  
 
5.4. Strategies for Retention 
Due to the low time burden (five study visits on site) at short intervals (maximum two weeks), we expect a low drop -out rate. Nevertheless, we are capturing data on possible reasons in case  of discontinuation .   
 
5.5.   Matching and Stratification  
Not applicable.  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   24 
Template  Version   2.0            2021- 09-09 5.6.   Randomization   and  Concealment  
Participants will be assigned  to active stimulation first or sham stimulation first using simple randomizat ion. 
5.7.   Blinding  
This is a double -blind study. Both participants and research staff will be blinded to the stimulation condition.  
  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   25 
Template  Version   2.0            2021- 09-09 6. Treatment Design: Procedures  
Description     
Transcranial alternating current stimulation (tACS)  
Participants will be stimulated with the commercial, CE -certified Neuroconn multiple channel (MC) stimulator. The 
use of this device routinely  received a non -significant risk ( NSR) designation on review by the full UNC IRB. The 
NeuroConn device description is as follows: The DC -STIMULATOR MC is a CE -certified medical device for conducting 
non-invasive transcranial current stimulation in humans. The DC -STIMULATOR MC is a micro -proces sor-controlled 
current source. It meets the highest safety standards thanks to (hardware - and software -based) multistage 
monitoring of the current path. By continuously monitoring electrode impedance it can detect insufficient contact 
with the skin and automatically terminate stimulation, maximizing patient safety. The device includes a digital 
display with various stimulation modes to be selected and stimulation parameters such as current strength, 
duration, fade -in and fade -out to be set.  
DC-STIMULATOR MC features:  
• 4 programmable, micro -processor -controlled constant current sources using 25ndependent  channels 
(optional: 16 channels)  
• For transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), cranial 
electrical stimulation (CES), galvanic vestibular stimulation (GVS) and transcranial random noise stimulation (tRNS)  
• 4 standard modes – tDCS (continuous stimulation) – pulse (cyclical stimulation activation/deactivation) – 
sinus (sinus wave) – noise (normally distributed)  
• Current strength and curve forms adjustable up to ±4,000 μA, AC current strength adjustable up to 8,000 
μA (peak- to-peak)  
• Frequencies adjustable up to 1,000 Hz, phase freely adjustable  
 
Electroencephalography (EEG):  A high -density EEG net (128  electrodes including electrooculography electrodes; EGI, Inc.) . Continuous qEEG 
recording will be performed . Sampling rate during the continuous recording will be 1 kHz with Cz as the reference 
and a channel  between Cz and Pz as ground, using an EGI system with SDK AmpServer Pro (Geodesic, Eugene,  
Oregon).  
 
Transcranial magnet stimulation (TMS) motor th resholding:  
Additionally, TMS motor thresholding (M. interosseus dorsalis I, with EMG electrodes) will be performed, as there 
is evidence suggest ing a relationship between the effect of tACS and brain excitability measured with single pulse 
TMS. We therefore measure cortical excitability by performing motor thresholding using single pulse  TMS 
(transcranial magnetic stimulation) during Visit 2.  A MagVenture  MagPro X100 TMS device  will be used.  
 
Dosing and A dministration    
The research team will first measure each participant 's head using the 10 -20 system to determine the electrode 
locations. Participant s will then be fitted with the 4  electrodes for stimulation: two 4.5 x4.5cm electrodes placed 
over T7/P7 and T 8/P8 (10/20 -EEG-system) . Electrodes will be carbon rubber, with Ten20 conductive paste applied.   
 
For gamma -tACS  40 Hz  will be applied (“natural target value”, for a review see (33) ). We have decided to apply 
control stimulation instead of sham stimulation as we have been able to  demonstrate visual side effects with 
bitemporal asynchronous stimulation (i.e. synchronized within one hemisphere) which differ according to stimulation frequency (phosphenes with higher frequencies, sensation of movements of the environment with lower fre quencies) . Hence, 21 Hz tACS will be applied for control stimulation (reasoning: no known specific effects 
on temporal lobe; close to gamma- stimulation and hence similar concerning side effects; not a harmonic frequency 
to 40 Hz).  An individual current amp litude will be determined before stimulation (for 21 Hz and 40 Hz; ramp -on 40s, 
continuous stimulation 20s; from 2mA peak -to-peak in steps of 0.25mA until “symptoms well tolerable for at least 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   26 
Template  Version   2.0            2021- 09-09 one hour”. The lower of the two current amplitudes from 40 Hz and 21 Hz will be applied for both stimulation 
conditions).  
 For both  stimulation  sessions, a ramp -on and ramp -off time of 40s will be applied.  
 Researchers  will monitor participant s during stimulation. Personnel will be thoroughly trained and have trainings 
documented on the  transcranial stimulation device and will be present during all stimulation sessions . Co-
investigator Andrea Seiler MD is a Swiss board -certified neurologist who will serve as supervisor for the stimulation 
study visits.  
 
During stimulation, the participant s will perform the following cognitive  tests presented on the computer screen  or 
on paper : RAVLT (Rey Auditory Verbal Learning Test) (26), a word  association test (8 word -pairs), Letter  Fluency 
(28), Stroop Color and Word Test (29) , Trail Making Test A and B (30), TAP (Test of Attentional Performance) (31) . 
The stimulator will be triggered by remote control from the experiment script and will administer stimulation during 
each single test. After each block of  stimulation, an  eyes -open  resting state EEG will be performed.  All stimulation 
involves 20 seconds of ramp -in time and 20 seconds of ramp -out time.  The total duration of the stimulation and  
testing is approximately 4 0 minutes.  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   27 
Template  Version   2.0            2021- 09-09 7. Schedule  of Activities and Procedures  
7.1. Table of Events  
 Procedure  Visit 0  
screening  
(online/phone)  Visit 1  
Baseline 
(from day 
after Visit 0 
to +14 
days)  Visit 2  
(day after 
Visit 1)  Visit 3 
(day after 
Visit 2)  Visit 4 
(telephone; 
5 days after 
Visit 2)  Visit 5  
(6-9 days 
after Visit 
2) Visit 6  
(day after 
Visit 5 ) Visit 7 
(telephone; 
5 days after 
Visit 5) 
Recruitment  Informed consent  X 
(oral)  X 
(written)        
 Eligibility 
assessments  X X       
 Enrollment and 
randomization   X       
Eligibility 
assessments  At least 4 hours 
of initial sleep -
EEG   x      
 No epileptiform 
discharges in 
baseline -EEG  x    x   
 No psychotropic 
treatment/illegal 
drugs within the 
last 3 months, no alcohol within the 
last 24 hours    x x  x x  
Intervention  (Control)  
Stimulation    X   X   
 Cognitive  
testing1   X X X (only 
verbal 
memory 
and 
associative 
verbal memory 
recall)  X X X (only 
verbal and 
associative verbal 
memory 
recall)  
 Sleep -EEG2  X 
(next night)  X 
(next 
night)    X 
(next 
night)    
 Actigraphy   X X X X X X  
 TMS Motor 
Thresholding    X      
Patient  
Reported  
Outcome  Subjective 
tolerability of 
sleep EEG    X X   X  
 Sleepiness  
(Karolinska Scale)    X X  X X  
 Sleep quality    X X  X X  
 Affect  
(PANAS)    X X  X X  
Safety  
Monitoring  Assessment of 
AEs   X X X X X X 
 
1 Standardized results of: RAVLT (Rey Auditory Verbal Learning Test) (26) , word  association  test, Letter  Fluency (28), 
Stroop Color and Word Test (29) , Trail Making Test A and B (30) , TAP (Test of Attentional Performance) (31) . 
2 Device worn  (yes/no) , hours of recording, sleep latency, sleep efficiency, amount of sleep spindles and slow wave 
sleep.  
 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   28 
Template  Version   2.0            2021- 09-09 7.2.   Screening  
The pre -screening can be performed via REDCap (questions 1, 2, 3 , 4); the whole screening (questions 1 -12) is 
performed via telephone. Result  of the screening procedure : eligible or not eligible.  
The following questions will be asked:  
1. Are you at least fifty years old? If not, then not eligible.   
2. Do you have an implanted device or metal in your head (including a cochlear implant), or do you have hearing 
aids? If yes, then not eligible.   
3.  Do you have a cardiac pacemaker? If yes, then not eligible.   
4. Alcohol Use Disorders Identification Test ( AUDIT ) 1-3: Gender: Woman / man / transgender / non- binary / prefer 
not to respond. Age: <65 years / ≥65 years? How often do you have a drink containing alcohol? How many drinks containing alcohol do you have on a typical day when you are drinking? How often do you have 4 (for females) or 5 (for males) – or more – drinks on one occasion? Cutoff (i.e. not eligible ): ≥7 for females and for males ≥ 65 years; ≥8 
for males <65 years.  5. Are you willing to abstain alcohol at least 24 hours before each study visit? If no, then not eligible.   
6. Have you ever been told by a healthcare provider that you have one of the following neurologic diseases: Epilepsy, sleep disorder (insomnia, sleep apnea, restless legs syndrome, parasomnia), stroke or transitory ischemic attack, cognitive impairment, ne urodegenerative disease (for example Alzheimer’s disease, Parkinson’s disease or 
amyotrophic lateral sclerosis), immune -mediated disease of the central nervous system, chronic infectious brain 
disease, brain tumor, traumatic brain injury with loss of consciousness and/or intracranial bleeding, chronic pain 
with the need for daily analgesic use? If yes, then not eligible.   
7. Did you ever have brain surgery? If yes, then not eligible.  
8. Have you been told by a healthcare provider that you have one of the following psychiatric diseases (in your 
lifetime or during the last three months): Schizophrenia (in your lifetime), obsessive compulsive disorder (OCD; in your lifetime), borderline personality disorder (in your lifetime), anxiety disorder (in your lifetime), bipolar disorder (in your lifetime), psychosis (in your lifetime), eating disorder (in your lifetime), depression (during the last three months)? If yes, then not eligible.  
9. Have you ever been told by a healthcare professional that you have one of the following medical conditions: Moderate to severe chronic obstructive pulmonary disease (COPD), abnormal kidney function (defined as estimated Glomerular Filtration Rate <60ml/ min), current liver disease (defined as hepatitis and/or liver cirrhosis), cancer, 
diabetes mellitus, cardiac disease (heart failure, myocardial infarct, atrial fibrillation and revascularization – all 
within the last three months)? If yes, then not eligib le. 
10. Do you work night shifts (last three months)? If yes, then not eligible.  
11. Do you usually go to bed after midnight (last three months)? If yes, then not eligible.   
12. Have you used psychotropic treatment or illegal drugs (including cannabis) within the last three months? If yes, then not eligible.  
 If online pre -screening is successfully completed and the participant  appears  eligible , the following message will 
appear : Please leave name, email, phone number and preferred time to be called by phone . 
 
The following information will be provided by  telephone:  
1. A brief summary of the study and its objectives.  
2. Instructions for the meeting at the lab:  
2.1 In the 24 hours before the visit: Please do not drink alcohol and do not drink more caffeine than you 
usually do.  
2.2 Please bring a list of all medications you regularly take (including those not prescribed by a healthcare 
professional).  
 
If not yet the case, the online questions will be completed  by phone . 
 
There may be up to 28 days between (pre -)screening and enrollment.  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   29 
Template  Version   2.0            2021- 09-09  
7.3.  Enrollment  
Visits 0 and 1  
The following procedures will occur:  
1. Signing of informed consent  
2. Completion of demographics and supplementary questions (mainly providing information about the cognitive 
state): Sex, racial/ethnic categories, education, living conditions, work status, clubs/social organizations, sports, 
social contacts, media consumption, concomitant medications list, caffeine consumption, alcohol consumption, smoking status.  
3. Specific questionnaires to exclude patients with indications for a sleep disorder, depression, anxiety disorder, cognitive impairment, epilepsy:  3.1 Sleep Quality Assessment PSQI (15): Screening for sleep disorders. Result: 0 -21 points. Exclusion if >5 points.  
3.2 Patient Health Questionnaire- 9 (16) : Screening for depression. Result: 0 -27 points. Exclusion if ≥5 points.  
3.3. General Anxiety Disorder -7 (17): Screening for anxiety disorder. Result: 0 -21 points. Exclusion if ≥10 points.  
3.4. Montreal Cognitive Assessment (MoCA): Screening for dementia. Result: 0 -30. Exclusion if <26.  
4. Complementary questionnaires to complete patient profile:  
4.1 Handedness Questionnaire (22)  
4.2 Behavioral Inhibition and Behavioral Activation Self Report Scales (BIS/BAS) (23): These scales are used to 
monitor the perceived sensitivity to reward and punishment. BIS/BAS is broken into four sub- scores: BIS (7 to 28), 
BAS drive (4 -16), BAS fun -seeking (4 -16), and BAS reward (7 -20). 
4.3 Basic sleep habits (bedtime, sleep latency, wakefulness during the night, waking time, total amount of sleep on average, optimal total amount of sleep)  
5. The following instructions will be given for the night and following day:  
851 How to use the EEG -headband the night before visit 2 (oral and written instructions, including sleep diary) ; how 
to use the actigraphy watch.  
5.2 To not consume more caffeine than usually. To please not drink alcohol.  
6. The participant will be randomized to the respective intervention for visit 2 (either gamma -tACS or first control  
stimulation).  
 
7.4.  Study Visits  
Visit 2 (day after Visit 1 ; afternoon/early evening, i.e. start between 12 pm and 6pm ) 
1. Questioning whether there has been any use of alcohol, psychotropic substances or illicit drugs during the past 
24 hours.  If yes, study participation is terminated. 
2. Questions to assess current sleepiness and mood, as this may affect the results of further testing:  
2.1 Questions for sleep quality the night before  
2.2 Karolinska Sleepiness Scale  (24) 
2.3 Positive And Negative Affect Schedule (PANAS) (25) 
3. Motor thresholding by TMS.  
4. Thresholding individual tACS amplitude.  
5. Gamma -tACS or control  stimulation (according to randomization) during the following cognitive tests , presented 
on a computer screen  (2 minutes of resting EEG without stimulation after each test; total duration approximately 
40 minutes ):  
5.1 Rey Auditory Verbal Learning Test (RAVLT , version 1 ) (26) 
5.2 Letter  Fluency ; letters F, A, S  (28) 
5.3 Stroop Color and Word Test (29) 
5.4 Trail Making Test A and B (30)  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   30 
Template  Version   2.0            2021- 09-09 5.5 Word association test; version 1  
5.6 Four subtests of the Test of Attentional Performance (TAP) (31): Alertness, Go/Nogo , Divided Attention, 
Visual Scanning  
5.7 RAVLT delayed recall  
6. Evaluation of side effects with open question (“Did you feel anything particular or note anything special during 
this session?”)  
7. The participant will be given the sleep diary for the second night with the EEG headband.  
 
Visit 3  (day after V isit 2; morning, i.e. start between 8am and 1 2pm) 
 
1.  Questioning whether there has been any use of alcohol, psychotropic substances or illicit drugs during the past 
24 hours.  If yes, the participant is  excluded.  
2. Questions to assess current sleepiness and mood, as this may affect the results of further testing:  
3.1 Questions for sleep quality the night before  
3.2 Karolinska Sleepiness Scale   
3.3 Positive And Negative Affect Schedule (PANAS)  
3. Cognitive follow -up testing 
4.1 RAVLT “ultra- delayed” recall; version 1  
4.2 Letter  fluency ; letters B, H, R  
4.3 Stroop Color and Word Test (SCWT)  
4.4 Trail Making Test Part A and B 
4.5 Word association recall; version 1  
4.6 Four subtests of the Test of Attentional Performance (TAP): Alertness, Go/NoGo, Divided Attention, 
Visual Scanning  
 
 
Visit 4  ( telephone; 5 days after Visit 2)  
Performed by telephone.  
1. Assessment of adverse events.  
2. RAVLT “ultra -delayed” recall; version 1.  
3. Word association recall; version 1.  
 
Visit 5  (6- 9 days after Visit 2; afternoon/early evening, i.e. start between 12 pm and 6pm )  
The day before: reminder (e -mail/SMS/phone call, depending on the participant's preference) of appointment on 
the following day - including request to abstain from alcohol and drugs as well as from excessive caffeine 
consumption.  
1. Questioning whether there has been any use of alcohol, psychotropic substances or illicit drugs during the past 
24 hours.  If yes, the participant is  excluded.  
2. Questioning if there is a new diagnosis.  If yes, the participant will be excluded if the diagnosis meets exclusion 
criteria.  
3. Questions to assess current sleepiness and mood, as this may affect the results of further testing:  
3.1 Questions for sleep quality the night before  
3.2 Karolinska Sleepiness Scale   
3.3 Positive And Negative Affect Schedule (PANAS)  
4. Gamma -tACS or control stimulation (according to randomization) during the following cognitive tests, presented 
on a computer screen (2 minutes of resting EEG without stimulation after each test):  
4.1 Rey Auditory Verbal Learning Test (RAVLT , version 2 )  
4.2 Letter  Fluency; letters F, A, S  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   31 
Template  Version   2.0            2021- 09-09 4.3 Stroop Color and Word Test  
4.4 Trail Making Test A and B  
4.5. Word association test; version 2  
4.6 Four subtests of the Test of Attentional Performance (TAP): Alertness, Go/NoGo, Divided Attention, 
Visual Scanning  
4.7 RAVLT delayed recall ; version 2  
5. Evaluation of side effects with open question (“Did you feel anything particular or note anything special during 
this session?”)  
6. The participant will be given the sleep diary for the third  night with the EEG headband.  
 
Visit 6  (day after V isit 5; morning, i.e. start between 8am and 1 2pm) 
1. The participant brings back the EEG -headband (used the night before). Data  quality check, review of sleep diary.  
2. Questioning whether there has been any use of alcohol, p sychotropic substances or illicit drugs during the past 
24 hours.  If yes, the participant is  excluded.  
3. Questions to assess current sleepiness and mood, as this may affect the results of further testing:  
3.1 Questions for sleep quality the night before  
3.2 Karolinska Sleepiness Scale   
3.3 Positive And  Negative Affect Schedule (PANAS)  
4. Cognitive follow -up testing 
4.1 RAVLT “ultra -delayed” recall; version 2  
4.2 Letter  fluency; letters B, H, R  
4.3 Stroop Color and Word Test (SCWT)  
4.4 Trail Making Test Part A and B 
4.5 Word association recall; version 2  
4.6 Four subtests of the Test of Attentional Performance (TAP): Alertness, Go/NoGo, Divided Attention, 
Visual Scanning  
 
Visit 7  (telephone; 5 days after Visit 5)  
Performed by telephone.  
1. Assessment of adverse events.  
2. RAVLT “ultra -delayed” recall.  
3. Word association recall; version 2.  
 
7.5.  Early Discontinuations   
Data to be Collected     
If the study participation has to b e terminated early by the investigators (due to safety concerns ), or if a participant 
chooses to withdraw from the study, including the case of not showing up for scheduled visits  on site ( Visits 1, 2, 3, 
5, 6) , the data  collected to date will not be included for the cognitive and slee p-EEG outcomes  and the participant 
will be replaced . However, early discontinuation will be included in the data set for the feasibility outcomes as 
appropriate.  Visits 4 and 7 are not mandatory for study completion.  
Criteria for Intervention Discontinuation     
An investigator may discontinue or withdraw a participant from the study for the following reasons:  
 
• Any clinical adverse event (AE), intercurrent illness or other medical condition, or situation occurs such that 
continued participation in the study  would not be in the best interest of the participant . 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   32 
Template  Version   2.0            2021- 09-09 • The participant  meets any exclusion criteria (either newly developed or not previously recognized)  or a 
reason for immediate early termination of participation . 
 
7.6.  Enrollees May Drop Out  
Participants may voluntarily withdraw from participation at any time, for any reason, with no penalty or loss of 
rights. In case of no -show, an attempt will be made to contact the participant (by mail or phone). The reasons for 
drop -out and missing data will be documented in the database.  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   33 
Template  Version   2.0            2021- 09-09 8. Statistical Analysis Plans  
8.1. Strategies that Apply to all the Aims  
All testing described below assumes a significance threshold of p = 0.05.  Analyses will be deemed to be statistically  
significant if the p -value is less than this threshold. An analysis that does not exceed this threshold will be considered 
inconclusive.  The proposed statistical analysis strategy acknowledges that no p -value can reveal the plausibility, 
presence, truth, or importance of an association or effect.  
 
There may be additional covariates included in the analysis. Data will be assessed for normality and, if deemed necessary, corrective procedures will be applied (e.g., log normalization).  This correction will be applied upon 
consideration of the variables themselves, and not based on the result of the intended analysis.  
 
8.2 Sample Description  
The sample will be described  using the following parameters: Age, sex, racial/ethnic categories, education, living 
conditions, work status, clubs/social organizations, sports, social contacts, media consumption, caffeine and alcohol consumption, smoking status. Whenever feasible, graphical methods will be used to describe the sample. 
Continuous data will be described using means , standard deviations, and confidence intervals , while categorical 
data will be described using counts/percentages.  
 
8.3 Aim-Specific Plans  
 Plans for Aim 1 .  
 
a) The proportion of participants in which stimulation and cognitive testing could  be completed will be calculated 
after both stimulation sessions, i.e. visit 2 and visit 4  (percentage and 95% confidence interval).  
   
 
 Plans for Aim 2 .  
To evaluate the effect of gamma -tACS on cognitive testing.  
 
a) Primary outcome: Ultra-d elayed verbal memory recall ( i.e. amount of words and word associations remembered 
the day after encoding  the RAVLT ) after gamma -tACS compared to after control stimulation, intra- and 
interindividually .  
We will perform a two -way or one -way repeated measure  ANCOVA  w ith time (baseline and post -treatment) and 
treatment (control  vs gamma -tACS) as within -subjects factors, and the order in which tACS will be applied  (tACS -
sham or control tACS) as covariate.  Post -hoc tests will be calculated after Bonferroni correction for multiple 
comparisons.  
 N
ull hypothesis: There is no difference between tACS and control stimulation for ultra -delayed memory recall  one 
day after stimulation . Alternative hypothesis: Memory recall is better after gamma -tACS than after control 
stimulation.  
 
 
b) Secondary outcomes: Verbal and associative learning (immediate and delayed recall, recall after 5 days ) and 
executive functions (results of Letter  Fluency , Stroop T est, Trail Making Test, Tests of Attentional Performance), 
comparison intra- and interindividually, after gamma -tACS and control stimulation (comparison of difference 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   34 
Template  Version   2.0            2021- 09-09 between visit 1 -visit 2 and visit 3 -visit 4; comparison of absolute results of visit 1 versus visit 3 and visit 2 versus visit 
4; statistical tests and covariates as in a)).  
Hypotheses are the same as for the primary outcome.  
 
 Plans for Aim 3 .  
To investigate the feasibility and adherence to wearable device (single -channel EEG during the night) . 
 
a) The proportion (percentage and 95% confidence interval)  of participants with at least four hours of EEG recording 
in the first night .  
  b) The proportion (percentage and 95% confidence interval) of participants with at least four hours of recorded 
nocturnal data  for each of all three nights.  
  
 
Plans for Aim 4 .  
To e valuate the effect of gamma -tACS compared to control  stimulation  on sleep EEG . Differences (individual level 
and group level , statistical tests as mentioned above ) of sleep latency (minutes from lights out to sleep onset), sleep 
efficiency (sleep duration in relation to time spent in bed), sleep spindle frequency (maximum number per hour) 
and slow wave activity (maximum minutes of slow wave sleep per hour) .  
The statistical method will be the same as for Aim 2.  
Null hypothesis: Sleep EEG does not change after gamma -tACS compared to the night after control stimulation.  
Alternative hypothesis: There is a higher amount of s leep spindles and/or slow wave sleep after gamma -tACS 
(compared to the control ).  
   
 
 Plans for Aim 5.  
To investigate whether there is a correlation (Pearson’s) between the stimulation- induced changes in cognitive 
testing scores and sleep EEG features  after gamma -tACS versus after control stimulation  (on individual and group 
level). This is an exploratory analysis.  
 
 
Plans for Aim 6.  
Comparison of cognitive test re sults after stimulation and sham on individual and group level using ANCOVA (see 
CT.gov) . This is an exploratory analysis.  
 
Plans for Aim 7. To investigate whether there is a correlation (Pearson’s) between the stimulation -induced changes 
in motor activity features (according to the wristband accelerometer results) after stimulation in general and after gamma -tACS  versus after control stimulation (on individual and group level). This is an exploratory analysis.  
 
Plans for Aim 8.  
To investigate whether there is a correlation (Pearson’s) between the motor threshold (TMS) and the  
subjective symptoms during tACS.  This is an exploratory analysis.  
 
  
8.4 Planned Interim Analyses  
No interim analyses will be performed.  
  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   35 
Template  Version   2.0            2021- 09-09 9. Sample Size Rationale  
We plan to recruit 28 healthy adults in this feasibility study (primary outcome). The sample size was computed such 
that the study has  95% power (alpha = 0.05) to reject the null hypothesis that 50% of the population of interest can 
complete the study procedures for an effect size of g = 0.3, meaning that if at least 80% of the study sample complete the pro cedures , feasibility in the population of at least 50% is established.  
10. Data Capture and Database Management  
10.1. Software for Data Capture  
Data will be entered  into a data capture system provided by TraCS Clinical Research Data Management Service 
(REDCap). REDCap is a 21 CFR Part 11 -compliant data capture system provided by the NC TraCS Institute at UNC. 
The data system includes password protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate.   
10.2. Responsibilities for Data Capture and Database Management  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site investigators (principal investigator and co -investigator) . The investigator is responsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data reported.  
Hardcopies of the study visit worksheets will be provided for use as source document worksheets for recording data for each participant enrolled in the study.  Data recorded in the electronic case report form (eCRF) derived from source documents should be consistent with the data recorded on the source documents.  
Clinical data (including adverse events (AEs), concomitant medications, and expected adverse reactions data) will be entered into REDCap. The data system includes password protection and internal quality checks, such as 
automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents.  Trained research personnel (including the co -investigator ) will have 
complete access to  the REDCap system, while the principal investigat or will have read -only ability.  
 
10.3. Study Records Retention  
According to the University of North Carolina at Chapel Hill’s Archives and Record Management Services schedule for General Records Retention and Disposition Schedule 6.10 , records will be kept for 5 years after the completion 
of the study or grant end date, whichever is later.  
 
 
 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   36 
Template  Version   2.0            2021- 09-09 11. Collection and Management of Tissue Specimens  
Not applicable.  
12. Safety Monitoring and Management  
12.1. Risk / Benefit Assessment  
Potential Risks:  
Risk of Confidentiality Breach: To avoid the uncommon event breaches in confidentiality, study documents that 
contain personal information, including the informed consent document,  will be kept in locked filing capinets 
in locked rooms. The document that links study ID numbers to perso nal identifying information will be a 
password -protected spreadsheet.  All data is stored in locked cabinets inside locked offices; electronic data will 
be stored only on password -protected computers, and data encryption methods will be used during 
communication between investigators. Interviews will be conducted over the HIPAA approved Zoom account. 
Only study  personnel will have access to the data. All study staff participate in annual human participant  training 
that includes education about responsibilities to minimize risk of confidentiality breach . 
 
Risk of Embarrassment: Self -report assessments contain questions regarding sensitive personal information. 
This uncommon risk is necessary in order to assess for relevant preexisting disorders . Participant s will be 
assured upon intake that only study personnel will see any clinical ratings and that self- identifying information 
will not be collected alongside HIPAA protected information.  
 
Risk of Injury and Discomfort:  
The side effects of tACS  are mild and transient; in fact, low intensity transcranial current  
stimulation, such as tACS, has been used for several years without any report of serious side effects.  
Furthermore, this stimulation mode has nothing to do with electroconvulsive therapy that applies  
many orders of magnitude higher stimulation current. Rather, transcranial current stimulation is so  
weak that it does not cause super -threshold activation of neurons.  
TACS does have some mild side effects, such as transient tingling, burning, pulsing sensation, or  
itching under the electrode sites (common). In a previous tACS trial we conducted, participants from  
all three groups of stimulation (two stimulation conditions, one was an active placebo group)  
reported either absent or mild side effects, and there was no difference between the groups with the  
exception of “flickering lights” (or phosphenes, p = 0.014). To monitor these mild side effects, we  
will be administering a stimulation questionnaire after each stimulation session to determine  
whether these effects were experienced and at what intensity. Research personnel is present during  
the full experiment. There have also been infrequent reports of reduced ability to focus, change in  
cognition, altered mood, headaches, and sleepiness. There is no evidence available that indicates that these potential side- effects are associated with stimulation versus study participation in general. In  
our previous depression work, we found no signal that supports an associated between any of these  side-effects 
and the administration of tACS. Both the application of the tACS and the EEG  
electrodes can cause mild inconvenience such as mild headaches from the pressure of applying the  
electrodes.  
The motor thresholding procedure that uses TMS has been used without reports of any serious  
side-effects. Some subjects report muscle twitching during stimulation and sometimes a headache  
(common, <50% incidence), but these possible effects are transient and do not persist after we stop  
stimulation. The transcranial stimulator used in this study was cleared by UNC Hospital Medical  
Engineering, the in -house engineering team of UNC hospitals that test the safety of medical devices.  
This TMS device has been cleared by the FDA for some indications, such as Major Depressive  
Disorder in patients, but it has not been evaluated by the FDA for this study. To mitigate  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   37 
Template  Version   2.0            2021- 09-09 uncomfortable side effects, during the study, we will ask about participants' comfort, and their  
participation will immediately be stopped if they are experiencing discomfort. In theory, there is a  
possibility that application of magnetic fields could induce a seizure. However, this has never been  
reported as occurring in general. In the broader field of TMS research, including riskier procedures  
than just motor thresholding, estimates of all seizure incidence is <0.02%, but due to its  
implausibility and theoretical nature, experts estimate that the likelihood of seizure during motor  
thresholding is much lower than this number. In the unlikely event of this occurring, trained medical  
professionals, including an expert in epilepsy and emergency seizure response, are on -site to  
respond. Furthermore, in order to mitigate this risk, we use multiple strategies. First, we screen  
participants based from participating in the study that present with any traits that may lower their  
seizure threshold or pose increased risk of seizure. These contraindications are well documented  
within the field and updated guidelines are released approximately every 10 years with the latest  
recommendation released in 2020 (Rossi et al. 2020). Contraindications screening is conducted  
during phone screening prior to the TMS session. Second, we have chosen our stimulation  
parameters to be within recommended safety guidelines. Third, we document regular trainings for  
personnel performing the motor thresholding procedure that matches standards recommended by  
expert consensus (Rossi et al. 2020, Fried et al. 2021). Fourth, we employ a comprehensive  
monitoring and adverse event assessment in each participant.  
Rossi S, Simone Rossi, Simone Rossi, Antal A, Bestmann S, Bikson M, Brewer CC, Brockmöller J,  
Carpenter LL, Cincotta M, et al. Safety and recommendations for TMS use in healthy subjects and  
patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines.  
Clinical Neurophysiology. 2020;132(1):269 –306. doi:10.1016/j.clinph.2020.10.003 
Fried PJ, Santarnecchi E, Antal A, Bartres -Faz D, Bestmann S, Carpenter LL, Celnik P, Edwards D,  
Farzan F, Fecteau S, et al. Training in the practice of noninvasive brain stimulation:  
Recommendations from an IFCN committee. Clinical Neurophysiology. 2021;132(3):819 –837.  
doi:10.1016/j.clinph.2020.11.018  
 
 
Potential Benefits:  
This study has not been designed to benefit the individual participants . However, the results from this study 
might be used to develop future interventions using non -invasive brain stimulation. 
 
12.2. Assessment of Safety  
If the participant indicates a non -zero answer to the question about suicide on the P HQ-9, a psychiatrist or clinical 
psychologist will be consulted with regards to next steps.  
 
12.3. Unanticipated Problems, Adverse Events, Serious Adverse Events  
Unanticipated Problems:  
The Office for Human Research Protections (OHRP) considers unanticipated problems involving risks to 
participants or others to include, in general, any incident, experience, or outcome that meets all  of the following 
criteria:  
 
• U
nexpected in terms of nature, severity, or frequency given (a) the research procedures that are described 
in the protocol -related documents, such as the Institutional Review Board (IRB) -approved research protocol 
and informed consent document; and (b) the  characteristics of the participant population being studied;  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   38 
Template  Version   2.0            2021- 09-09 • Related or possibly related to participation in the research (“possibly related” means there is a reasonable 
possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research); and  
• Suggests that the research places participants or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) than was previously known or recognized.  
 
 
 
Adverse Event (AE) Definitions:  
Adverse event means any untoward medical occurrence associated with the use of an intervention in  humans, 
whether considered intervention -related (21 CFR 312.32 (a )).  
 
 
Serious Adverse Events (SAE) Definition: <insert text>     
An a dverse event (AE) or suspected adverse reaction is considered "serious" if, in the view of the investigator , 
it results in any of the following outcomes: death, a life -threatening adverse event, inpatient hospitalization or 
prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the 
ability to conduct normal  life functions, or a congenital anomaly/birth defect. Important medical events that 
may not result in death, be life -threatening, or require hospitalization may be considered serious when, based 
upon appropriate medical judgment, they may jeopardize the p articipant  and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug 
abuse.  
 
Grading the Severity of Adverse Events and Events of ‘Special Interest’:   
All adverse events (AEs) will be assessed by the principal investigator and/or co -investigator(s) using the 
following guidelines:  
 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily activities.  
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic measures. 
Moderate events may cause some interference with functioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic drug therapy or other 
treatment. Severe events are usually potentially life -threatening or incapacitating.  Of note, the term 
“severe” does not necessarily equate to “serious” . 
 
Relatedness Definition:   
All adverse events (AEs) must have their relationship to study intervention assessed by the principal investigator 
and co -investigator(s) who examines and evaluates the participant based on temporal relationship and their  
clinical judgment. The degree of certainty about causality will be graded using the categories below. In a clinical trial, the study product must always be suspect.  
 
• Definitely Related – There is clear evidence to suggest a causal relationship, and other possible contributing 
factors can be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a plausible time relationship to study intervention administration and cannot be explained by concurrent 
disease or other drugs or chemicals. The response to withdrawal of the study intervention (dechallenge) 
should be clinically plausible. The event must be pharmacologically or phenomenologically definitive, with use of a satisfactory rechallenge procedure if necessary.  
• Probably Related – There is evidence to suggest a causal relationship, and the influence of other factors is 
unlikely. The clinical event, including an abnormal laboratory test result, occurs within a reasonable time after administration of the study intervention, is unlik ely to be attributed to concurrent disease or other 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   39 
Template  Version   2.0            2021- 09-09 drugs or chemicals, and follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge 
information is not required to fulfill this definition.  
• Potentially Related – There is some evidence to suggest a causal relationship (e.g., the event occurred 
within a reasonable time after administration of the trial medication). However, other factors may have 
contributed to the event (e.g., the participant’s clinical condition, other concomitant events). Although an 
AE may rate only as “possibly related” soon after discovery, it can be flagged as requiring more information and later be upgraded to “probably related” or “definitely related”, as appropriate.  
• Unlikely to be related – A clinical event, including an abnormal laboratory test result, whose temporal 
relationship to study intervention administration makes a causal relationship improbable (e.g., the event did not occur within a reasonable time after administration of the st udy intervention) and in which other 
drugs or chemicals or underlying disease provides plausible explanations (e.g., the participant’s clinical condition, other concomitant treatments).  
Not Related – The AE is completely independent of study intervention administration, and/or evidence exists 
that the event is definitely related to another etiology. There must be an alternative, definitive etiology 
documented by the clinician.  
 
Expectedness Definition:   
The prin cipal investigator, with input from the co -investigator when necessary, will determine whether an 
adverse event (AE) is expected or unexpected in this population. The principal investigator is an expert in non -
invasive brain stimulation and will provide his expert opinion regarding this as well. An AE will be considered 
unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the study  intervention.  
 
AE and SAE As sessment, Follow -up Procedures:    
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the attention of study personnel during study visits, or the study participant  may report AE or SAEs outside of a scheduled study visit.  
All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate case report form (CRF). Information to be collected includes event description, time of onset, clinician’s assessment of severity, relationship to study product (assessed only by those with the training and authority to make a diagnosis), and time of resolution/stabilization of the event. All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution. Any medical condition that is present at the time that the participant  is screened will be considered 
as baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE.   Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as 
intermittent require documentation of onset and duration of each episode.   
 
Reportin g and Documentation Procedures:    
 
What event is reported  When is event 
reported  By whom is event 
reported  To whom is event 
reported  
Fatal or life -threatening 
unexpected, suspected 
serious adverse 
reactions  Within 24 hours of 
initial receipt of 
information  Investigator  Local/internal IRB  
Non -fatal, non-life-
threatening 
unexpected, suspected 
serious adverse 
reactions  Within 48 hours of 
initial receipt of 
information  Research Personnel  Local/internal IRB  
 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   40 
Template  Version   2.0            2021- 09-09 Unanticipated adverse 
device effects  Within 10 working days 
of investigator first 
learning of effect  Investigator  Local/internal IRB  
 
Unanticipated Problem 
that is not an SAE  Within 7 days of the 
investigator becoming 
aware of the problem  Investigator  Local/internal IRB  
 
 
 Participant Notification of New Information :
 
Any new information gained during the study that may affect a participant’s willingness to continue in the study  
will be reported to all currently enrolled participant . 
 
12.4. Safety Monitoring  
Research personnel will record all reportable events with start dates occurring any time after informed consent 
is obtained until the last day of study participation. At each study visit, research personnel will inquire about 
the occurrence of AE/SAEs sinc e the last visit. All AEs including local and systemic reactions not meeting the 
criteria for SAEs will be captured on the appropriate case report form (CRF). Information to be collected includes 
event description, time of onset, clinician’s assessment of severity, relationship to study product (assessed only 
by those with the training and authority to make a diagnosis), and time of resolution/ stabilization of the event. 
All AEs will be followed to adequate resolution.  
 
12.5. Study Suspension / Early Termination of the Study  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. If 
the study is prematurely terminated or suspended, the principal i nvestigator will promptly inform research 
staff, study participants , and the IRB and will provide the reason(s) for the termination or suspension.  Study 
participants  will be contacted, as applicable, and be informed of changes to study visit schedule.   
 
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, and satisfy 
the IRB . 
  
13. Regulatory, Ethical, and Study Oversight Specifications  
 
13.1. Informed Consent Process  
 
 13.1.1.  Consent/Assent and Documents Provided to Participants  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   41 
Template  Version   2.0            2021- 09-09 Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and 
continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of tACS will be provided to the participants.  
Consent forms describing in detail the study intervention, study procedures, and risks are given to the participant 
and written documentation of informed consen t is required before visit 1.  
 
 13.1.2.  Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and 
continues throughout the individual’s study participation. Consent forms will be Institutional Review Board (IRB) -
approved and the participant will be asked to read and review the document. The investigator will explain the research study to the participant and answer any questions that may arise. A verbal explanation will be provided in terms suited to the participant’s comprehension of the purposes, procedures, and potential risks of the study and 
of their rights as research participants.  Participants will have the opportunity to carefully review the written consent 
form and ask questions prior to signing. The participants have the opportunit y to discuss the study with their family 
or surrogates or think about it prior to agreeing to participate. The participant will sign the informed consent document prior to any procedures being done specifically for the study. Participants must be informed that participation is voluntary and that they may withdraw from the study at any time, without prejudice. A copy of the informed consent document will be given to the participants for their records. The informed consent process will be conducted and documented in the source document (including the date), and the form signed, before the participant undergoes any study -specific procedures. The rights and welfare of the participants will be protected by 
emphasizing to them that the quality of their medical care will not be adversely affected if they declin e to participate 
in this study.  
13.2. Study Discontinuation and Closure  
See sections 7.5 and 12.5.  
 
13.3. Confidentiality and Privacy  
Participant confidentiality and privacy is strictly held in trust by the participating investigators, their staff, and the research team.  This confidentiality is extended t o cover  the clinical information relating to participants.  Therefore, 
the study protocol, documentation, data, and all other information generated will be held in strict confidence.  In 
addition, a ll research activities will be conducted in an as private as possible  setting . 
 All data will only be referenced by dummy identifier code. Data will be stored on a password protected computer. A key connecting names and identifier code numbers will be kept  in a locked cabinet, accessible only by research 
personnel. All data will be stored and analyzed on password protected computers, also only accessible by research personnel. Participants will not be identified in any report or publication about this study and there is no risk of 
deductive disclosure . At the end of the study, all records will continue to be kept in a secure location for as long a 
period as dictated by the IRB.  
 Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be entered into TraCS Clinical Research Data Management Service (REDCap). The database system provides secure web -based 
data entry with the data s tored on servers that are maintained by TrACS. The data is encrypted during transmission. 
The servers are located in a secure campus area with all appropriate physical security measures in place. The web and database servers are monitored by the TraCS IT staff, patched frequently, and scanned by a third -party vendor 
to ensure that they are protected against known vulnerabilities. The scanning application is the standard service for the entire campus. Access is by individual user id and is restricted to the forms and/or functions that the user needs 
to have.  
  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   42 
Template  Version   2.0            2021- 09-09 13.4. Future Use of Stored Specimens and Data  
Data collected for this study will be analyzed and stored within the Carolina Center for Neurostimulation/Frohlich 
Lab. After the study is completed, the data will be fully de -identified and archived within a locked file cabinet within 
the Carolina Center for Neurostimulation.  
 
13.5. Key Roles and Study Governance  
 
Principal Investigator   Medical Monitor  
Flavio Frohlich, PhD   Nathan Walker MD Assistant Professor of Neurology  
The University of North Carolina at Chapel Hill    UNC – Chapel Hill   
Department of Psychiatry    
919-966-4584   (919) 966 -9343  
flavio_frohlich@med.unc.edu    nwalker@neurology.unc.edu  
 
 
13.6. Safety Oversight 
Safety oversight will be under the direction of the principal investigator. He will review all adverse events timely 
and serious adverse events and changes in the suicidality and mania ratings immediately. Based on his review, continuation of participant’s participation is decided. All SAE or unanticipated AE will be reported to the local IRB.  
13.7. Clinical Monitoring Plan (CMP)  
The purpose of the monitoring plan is to present the approach of the Carolina Center for Neurostimulat ion to 
monitoring clinical trials.  The plan facilitates compliance with good clinical practice.  
 (a) The rights and well- being of human participants  are protected.  
(b) The reported trial data are accurate, complete, and verifiable from source documents.  
(c) The conduct of the trial is in compliance  with the currently approved protocol/amendment(s), with GCP, and 
with applicable regulatory requirement(s).  
 This section identifies key monitoring activities and specifies the data to be reviewed over the course of a clinical trial.  This is a single site, investigator initiated, clinical trial so there will be no site monitoring plan in place . 
 
The Carolina Center for Neurostimulation monitoring plan:  
The latest version of the approved IRB application for this clinical trial will be followed at all times. This responsibility  
falls in the hands of the trained research personnel.  If at any time there is a deviation from protocol, the deviation 
form protocol log will be filled out. All team members will be trained on how and when to use this log.   
 
Data will be verified for completeness following every study session and all data will be entered into REDCap, a secure online database. After a participant  has completed their participation (full completion through all visits  or 
because they withdrew prior to completion), data will be rereviewed for completeness and accuracy. After all data has been collected, data will be re -reviewed by another lab member who was not involved with the data collection 
process.   
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   43 
Template  Version   2.0            2021- 09-09 AE and SAE are clearly defined in the Master Protocol. Documents of AE and SAE can be found in the study binder 
on file . It is responsibility of trained research personnel to report all events to the PI.  
 The principal investigator will have read -only access to the REDCap database.  This allows the principal investigator  
to view reports that provide information on any missing data on an individual participant  basis, but does not allow 
them to add, change or input any data.  
 
13.8. Q uality Assurance and Quality Control  
The Carolina Center for Neurostimulation will conduct internal quality management of study conduct, data collection, documentation, and completion. Following written Standard Operating Procedures (SOPs), research personnel will verify that the clinical trial is conducted and data are generated and biological specimens are collected, documented (recorded), and reported in compliance with the protocol, International Conference on Harmonisation Good Clinical Practice (ICH GCP), and applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
 
13.9. Prot ocol Deviations  
All deviations from the protocol will be addressed in study participant  source documents. The researcher will 
complete a Protocol Deviation Log using the participant  code as the identifier. This form will collect information 
such as the date the deviation occurred, details of what the deviation consisted of, any corrective and preventative actions that were taken as a result of the dev iation, and the date that the principal investigator and IRB were 
notified. The principal investigator  will review the information and initial once approved. A completed copy of the 
Protocol Devi ation Form will be maintained in the regulatory file, as well as in the participant ’s source document. 
The site study staff will be responsible for knowing and adhering to their IRB requirements.  
 
13.10. Publication and Data Sharing Policy  
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded Clinical Trial 
Information and the Clinical Trials Registration and Results Information Submission rule. As such, this trial will be registered at ClinicalTrials.gov , and results information from this trial will be submitted to ClinicalTrials.gov.  In 
addition, every attempt will be made to publish results in peer -reviewed journals.   
 
13.11. Conflict of Interest Policy  
The independence of this study from any actual or perceived influence is critical. Any conflict of interest for any persons who have a role in the design, conduct, analysis, publication, or any aspect of this trial will be disclosed and managed by the UNC Conflict of Interest Office. If necessary, for persons who have a perceived conflict of interest, management will be provided again by the UNC Conflict of Interest office.  
  
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   44 
Template  Version   2.0            2021- 09-09 14.Additional Considerations  
 
Not applicable.  
 
15. References  
 1.  Luck T, Roehr S, Rodriguez FS, Schroeter ML, Witte AV, Hinz A, et al. Memory -related subjective cognitive 
symptoms in the adult population: Prevalence and associated factors - results of the LIFE- Adult -Study. BMC 
Psychol. BMC Psychology; 2018;6(1):1– 15.  
2.  Dzierzewski JM, Perez E, Ravyts SG, Dautovich N. Sleep and Cognition: A Narrative Review Focused on Older Adults. Sleep Med Clin. 2022 Jun;17(2):205 –22.  
3.  Rasch B, Born J. About sleep’s role in memory. Physiol Rev. 2013 Apr;93(2):681– 766.  
4.  Klinzing JG, Niethard N, Born J. Mechanisms of systems memory consolidation during sleep. Nat Neurosci. United States; 2019 Oct;22(10):1598 –610.  
5.  Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science (80 - ). 
2020;370(6512):50 –6.  
6.  Grover S, Nguyen JA, Reinhart RMG. Synchronizing Brain Rhythms to Improve Cognition. Annu Rev Med. United States; 2021 Jan;72:29 –43.  
7.  Booth SJ, Taylor JR, Brown LJE, Pobric G. The effects of transcranial alternating current stimulation on memory performance  in healthy adults: A systematic review. Cortex. Italy; 2022 Feb;147:112 –39.  
8.  Grover S, Wen W, Viswanathan V, Gill CT, Reinhart RMG. Long -lasting, dissociable improvements in working 
memory and long- term memory in older adults with repetitive neuromodulation. Nat Neurosci. Springer US; 
2022;  
9.  Nomura T, Asao A, Kumasaka A. Transcranial alternating current stimulation over the prefrontal cortex enhances episodic memory recognition. Exp Brain Res [Internet]. Springer Berlin Heidelberg; 2019;237(7):1709– 15. Available from: https://doi.org/10.1007/s00221 -019-05543 -w 
10.  Javadi AH, Glen JC, Halkiopoulos S, Schulz M, Spiers HJ. Oscillatory reinstatement enhances declarative memory. J Neurosci. 2017;37(41):9939 –44.  
11.  Ambrus GG, Pisoni A, Primaßin A, Turi Z, Paulus W, Antal A. Bi- frontal transcranial alternating current 
stimulation in the ripple range reduced overnight forgetting. Front Cell Neurosci. 2015;9(September):1 –7.  
12.  Sederberg PB, Schulze -Bonhage A, Madsen JR, Bromfield EB, McCarthy DC, Brandt A, et al. Hippocampal and 
neocortical gamma oscillations predict memory formation in humans. Cereb Cortex. 2007;17(5):1190 –6.  
13.  Van Quyen M Le, Muller LE, Telenczuk B, Halgren E, Cash S, Hatsopoulos NG, et al. High- frequency oscillations 
in human and monkey neocortex during the wake -sleep cycle. Proc Natl Acad Sci U S A. 2016;113(33):9363–
8.  
14.  Topolnik L, Tamboli S. The role of inhibitory circuits in hippocampal memory processing. Nat Rev Neurosci. Springer US; 2022;23(8):476 –92.  
15.  Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new 
instrument for psychiatric practice and  research. Psychiatry Res. Ireland; 1989 May;28(2):193 –213.  
16.  Kroenke K, Spitzer RL, Williams JB. The PHQ -9: validity of a brief depression severity measure. J Gen Intern 
Med. 2001 Sep;16(9):606– 13.  
17.  Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the 
GAD -7. Arch Intern Med. United States; 2006 May;166(10):1092– 7.  
18.  Prevention C for DC and. Planning and Implementing Screening and Brief Intervention for Risky Alcohol Use: A Step -by-Step Guide for Primary Care Practices. 2014;  
19.  Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, et al. The AD8: a brief informant interview to detect dementia. Neurology. United States; 2005 Aug;65(4):559 –64.  
20.  Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive 
Effects of tACS on Memory and Sleep -EEG   Version 1. 4 
Protocol Number   08/15/2023 
Interventional or Observational Protocol                                                                                                                                                                                 Page   45 
Template  Version   2.0            2021- 09-09 Assessment, MoCA: a brief screening tool for mild  cognitive impairment. J Am Geriatr Soc. United States; 
2005 Apr;53(4):695– 9.  
21.  Ottman R, Barker -Cummings C, Leibson CL, Vasoli VM, Hauser WA, Buchhalter JR. Validation of a brief 
screening instrument for the ascertainment of epilepsy. Epilepsia. 2010 Feb;51(2):191 –7.  
22.  Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. England; 1971 Mar;9(1):97– 113.  
23.  Carver CS and TLW. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: the BIS/BAS scales. J Pers Soc Psychol. 1994;(Vol 67(2)):319 –33.  
24.  Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. England; 1990 May;52(1– 2):29 –37.  
25.  Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the  PANAS scales. J Pers Soc Psychol. United States; 1988 Jun;54(6):1063 –70.  
26.  Schmidt M. Rey Auditory Verbal Learning Test: A handbook. Los Angeles, CA: Western Psychological Services; 1996.  
27.  Spreen, O, Strauss E. A compendium of neuropsychological tests: administration, norms and commentary. New York Oxford Univ Press. 1991;  
28.  Machado TH, Fichman HC, Santos EL, Carvalho VA, Fialho PP, Koenig AM, et al. Normative data for healthy elderly on the phonemic verbal fluency task - FAS. Dement Neuropsychol. 2009;3(1):55– 60.  
29.  Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;  
30.  R.M. R. Validity of the Trail Making test as an indicator of organic brain damage. Percept Mot Ski. 1958;  
31.  Zimmermann P. FB. Testbatterie zur Aufmerksamkeitsprüfung (TAP). 2002;  
32.  Kucewicz MT, Berry BM, Kremen V, Brinkmann BH, Sperling MR, Jobst BC, et al. Dissecting gamma frequency activity during human memory processing. Brain. 2017;140(5):1337 –50.  
33.  McDermott B, Porter E, Hughes D, McGinley B, Lang M, O’Halloran M, et al. Gamma Band Neural Stimulation 
in Humans and the Promise of a New Modality to  Prevent and Treat Alzheimer’s Disease. J Alzheimers Dis. 
2018;65(2):363 –92.  
34.  Antal A, Alekseichuk I, Bikson M, Brockmöller J, Brunoni AR, Chen R, et al. Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines. Clin Neurophysiol [Internet]. International Federation of Clinic al Neurophysiology; 2017;128(9):1774 –809. Available from: 
http://dx.doi.org/10.1016/j.clinph.2017.06.001  
35.  Fröhlich F, McCormick DA. Endogenous electric fields may guide neocortical network activity. Neuron. United States; 2010 Jul;67(1):129 –43.  
  
 